TB drug

Published on June 2016 | Categories: Documents | Downloads: 66 | Comments: 0 | Views: 399
of 56
Download PDF   Embed   Report

Comments

Content

1234567890123456789012345678901212345678901234567890123456789012123456789012345
1234567890123456789012345678901212345678901234567890123456789012123456789012345
1234567890123456789012345678901212345678901234567890123456789012123456789012345
1234567890123456789012345678901212345678901234567890123456789012123456789012345
1234567890123456789012345678901212345678901234567890123456789012123456789012345
1234567890123456789012345678901212345678901234567890123456789012123456789012345
Topic Review
1234567890123456789012345678901212345678901234567890123456789012123456789012345
1234567890123456789012345678901212345678901234567890123456789012123456789012345
¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
Çѵ¶Ø»ÃÐʧ¤
ì
1.
à¾×èÍÊÒÁÒöÇÔ¹Ô¨©Ñ
Â
´ÙáÅÃÑ¡ÉÒáÅеԴµÒÁ¼Ùé»èÇÂÇѳâää´é
*
°ÔµÔ¹Ñ¹—
ì͹ØÊóìǧÈìªÑ
Â
** ©Ñ¹ªÒÂ
Êԗ¸Ô¾Ñ¹¸
ìØ2. à¾×èÍÃÙé¨Ñ¡ÂҗÕèãªéÃÑ¡ÉÒÇѳâä
¡Åä¡¡ÒÃÍ͡ė¸
ìÔ¢¹Ò´ÇÔ¸ÕãªéµÅÍ´
¨¹¼Å¢éÒ§à¤Õ§¢Í§ÂÒ
3.
ÊÒÁÒö¹Ó¤ÇÒÁÃÙé—Ñé§ã¹Í´ÕµáÅлѨ¨ØºÑ¹ÁÒÃǺÃÇÁáÅлÃÐÁÇżÅ
à¾×è͹ӼšÒÃÇÔ¨ÑÂÇÒÃÊÒÃä»ãªé»ÃСͺ¡ÒôÙáÅÃÑ¡ÉÒ¼Ùé»èÇÂÇѳâä
º—¤Ñ´Âè
Í
㹻Ѩ¨ØºÑ¹¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä—ÕèàËÁÒÐÊÁ—ÕèÊØ
´
ÁÕá¹Ç—Ò§àʹÍ
á¹Ð
â´Â¡ÅØèÁ¼ÙéàªÕèÂǪҍ㹻ÃÐà—È—Õè¾Ñ²¹ÒáÅé
Ç
àªè
¹
ÊËÃÑ°ÍàÁÃÔ¡Ò
(American Thoracic Society ¾.È. 2537) ¡Ñ
º
ÊËÃÒªÍҳҨѡÃ
(British Thoracic Society ¾.È. 2540) áÅÐͧ¤ì¡ÒùҹҪҵÔä´éá¡è
ͧ¤ì¡ÒÃ͹ÒÁÑÂâÅ¡ (WHO Tuberculosis Unit ¾.È. 2540) áÅÐ
International Union Against Tuberculosis and Lung Disease
(IUATLD ¾.È. 2540) ¡ÅèÒÇä´éÇèÒ¡ÒÃÃÑ¡ÉÒÃÐÂÐÊÑ鹗Õèãªé㹻Ѩ¨ØºÑ
¹
à»ç¹ÃкºÂÒÃдѺ¹Ò¹ÒªÒµÔËÃ×ÍÃдѺâÅ¡
—ÕèÁÕ»ÃÐÊԗ¸ÔÀÒ¾áÅÐ

»ÃÐÊԗ¸Ô¼Å´Õ—ÕèÊØ
´
—Õè¨ÐÃÑ¡ÉÒ¼Ùé»èÇÂÇѳâäãËéËÒÂä´éà¡×ͺÃéÍÂÅÐ 100
¶éÒ¼Ùé»èÇÂä´éÃѺÂÒÊÁèÓàÊÁͤú¶éǹ
*
ᾗÂì»ÃШӺéÒ¹
ÀÒ¤ÇÔªÒÍÒÂØÃÈÒʵÃ
ì
¤³ÐᾗÂÈÒʵÃ
ì
¨ØÌÒŧ¡Ã³ìÁËÒÇԗÂÒÅÑ
Â
**ÀÒ¤ÇÔªÒÍÒÂØÃÈÒʵÃ
ì
¤³ÐᾗÂÈÒʵÃ
ì
¨ØÌÒŧ¡Ã³ìÁËÒÇԗÂÒÅÑ
Â

¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
Çѳâäà»ç¹âäµÔ´àª×éÍã¹Á¹ØÉÂì—Õ辺ÁÒ¹Ò¹ËÅÒÂ
¾Ñ¹»Õ¨Ò¡¡ÒÃÈÖ¡ÉÒ«Ò¡ÁÑÁÁÕèÍÕÂÔ»µ
쾺ÇèÒÁÑÁÁÕèÁÕ¤ÇÒÁ
¼Ô´»¡µÔ¢Í§¡Ãд١ÊѹËÅѧáÅоºªÔé¹Êèǹ¢Í§´ÕàÍç¹àÍ
(DNA) ¢Í§àª×éÍÇѳâäÍÂÙè㹡Ãд١¹Ñé
¹
áÊ´§ãËéàËç
¹
ÇèÒàª×é͹Õé—ÓãËéà¡Ô´âäã¹Á¹ØÉÂìÁÒµÅÍ´
¡èÍãËéà¡Ô´»ÑËÒ
ÊÒ¸ÒóÊØ¢—Õè¤Ø¡¤ÒÁ»ÃЪҡ×ÑèÇâÅ¡
â´Â੾ÒлÃÐà—È
¡ÓÅѧ¾Ñ²¹Ò
Çѳâäà¡Ô´¨Ò¡àª×éÍ¡ÅØè
Á
Mycobacterium
tuberculosis ¤é¹¾º¤ÃÑé§ááâ´Â Robert Koch ã¹»Õ
¾Ø—¸ÈÑ¡ÃÒª 2425 à»ç¹àª×é͗çá—è
§
¢¹Ò´ 0.5 ¶Ö§ 3
äÁ¤Ã͹
äÁèÊÃéҧʻÍÃ
ìäÁèµÔ´ÊÕá¡ÃÁ
äÁè¶Ù¡ÅéÒ§´éÇÂ
¡Ã´ÍÑÅ¡ÍÎÍÅ
ì¨Ö§¶Ù¡àÃÕ¡Çè
Ò
áÍÊÔ´¿ÒÊ (acid-fast
bacilli) Çѳâä»Í´ÁÑ¡¨ÐµÔ´µèÍâ´Â¡ÒÃÊÙ´àÍÒÅÐÍͧ
àÊÁËТͧ¼Ùé»èÇ—ÕèäÍ
¨ÒÁ
¾Ù
´
ËÑÇàÃÒÐËÃ×ÍËÒÂã¨Ã´
à¢éÒä»ã¹»Í´â´ÂµÃ§
â´Âàª×éÍÇѳâäÁÕ¢¹Ò´àÅç¡¡Çè
Ò
10 äÁ¤Ã͹
ÊÒÁÒöà¢éÒ件֧Êèǹ»ÅÒÂÊØ´¢Í§—Ò§à´Ô
¹
ËÒÂã¨
áÅСèÍãËéà¡Ô´âä
´Ñ§¹Ñ鹨֧ÁÑ¡ÁÕ»ÃÐÇѵÔÊÑÁ¼Ñ
Ê
ã¡ÅéªÔ´¡Ñº¤¹—Õèà»ç¹âä
Êèǹ¡ÒõԴµèÍâ´Â—Ò§Í×è¹¹Ñ
º
ÇèÒÁÕâÍ¡ÒʹéÍÂÁÒ¡
—ÕèÍÒ¨¾ºä´é¡çâ´Â¡Òô×èÁ¹ÁÇÑÇ´Ôºæ
—Õèä´é¨Ò¡ÇÑǗÕèà»ç¹Çѳâä
ËÃ×Íâ´Â¡ÒáÅ×¹àÍÒàª×é͗ÕèµÔ
´
ÁҡѺÍÒËÒÃËÃ×ÍÀÒª¹Ð
àª×éͨÐà¢éҗҧµèÍÁ—͹«ÔÅËÃ×
Í

ÅÓäÊéáÅéÇà¢éÒä»ÍÂÙèã¹µèÍÁ¹éÓàËÅ×ͧ
«Ö觺ҧ¤ÃÑé§ÍÒ¨
ÅØ¡ÅÒÁà¢éÒ¡ÃÐáÊàÅ×Í´ä»Âѧ»Í´
ÊÁͧ
¡ÃдÙ
¡
äµ
ËÃ×ÍÍÇÑÂÇÐÍ×è¹æ
ä´é¶Ö§áÁéÇèÒàª×éÍÇѳâäã¹ÅÐÍͧ½ÍÂ
äÁèà¤Å×è͹äËÇ
¶Ù¡—ÓÅÒÂä´é§èÒ´éǤÇÒÁÃé͹
¤ÇÒÁáËé
§
áʧᴴ
ËÃ×Íáʧ-ÍÑŵÃéÒäÇâÍàŵ
ÍÂèÒ§äáçµÒÁ
¤ÇÃ
᡼Ùé»èÇÂÍÂèÒ§¹éÍ 2 ÊÑ»´ÒËìáá¢Í§¡ÒÃÃÑ¡ÉÒ
à¾×è
Í
Å´¡ÒÃá¾Ãèàª×éÍÇѳâää»ÊÙèºØ¤¤Å¢éÒ§à¤Õ§
â´ÂÊèǹãˍè
¾ºàª×éÍâä¹Õé㹻ʹ
ÍÂèÒ§äáçµÒÁÍÒ¨¾ºã¹ÍÇÑÂÇÐÍ×è¹æ
ä´é¶Ö§Ë¹Öè§ã¹ÊÒÁ¢Í§¼Ùé»èÇÂÇѳâäà»ç¹âä—ÕèÃÑ¡ÉÒãËéËÒÂ
¢Ò´ä´éáµè¶éÒäÁèÃÑ¡ÉÒ
¤ÃÖè§Ë¹Ö觢ͧ¼Ùé»èÇÂÍÒ¨àÊÕªÕÇÔ
µ
ä´éÀÒÂã¹ 5 »Õ1
â´ÂʶԵԗÕèÃǺÃÇÁâ´Âͧ¤ì¡ÒÃ͹ÒÁÑÂâÅ¡2
µÑé§áµè
»Õ¾.È. 2534 áÅЗº—ǹãËÁèàÁ×è
Í
¾.È. 2541
¾ºÇè
Ò
»ÃЪҡÃâÅ¡¶Ö§Ë¹Öè§ã¹ÊÒÁ
ËÃ×Í»ÃÐÁÒ³ 1,900
ÅéÒ¹¤¹3 µÔ´àª×éÍÇѳâä
µèÍÁÒ»Õ¾.È. 2544 ÁÕ¼Ùé»èÇÂ
ÇѳâäãËÁèÍغѵԢÖé¹ 8.5 ÅéÒ¹¤¹
áÅÐàÊÕªÕÇÔµÃèÇÁ 23
ÅéÒ¹¤¹µèͻիÖè§ÊÙ§¡ÇèÒ¡ÒÃÃкҴãˍèã¹Í´Õ
µ
â´Â
Êèǹãˍèà¹×èͧ¨Ò¡¡ÒÃÃкҴ¢Í§¡ÒõԴàª×éÍàÍ´Ê
ìáÅÐ
ÇѳâäÂѧ¤§à»ç¹ÊÒà˵ءÒõÒ¢ͧ»ÃЪҡÃÁÒ¡¡ÇèÒâä
µÔ´àª×éÍà´ÕèÂÇÍ×è¹æ—Ñé§ÊÔé
¹
ÁÒ¡¡ÇèÒÃéÍÂÅÐ 95 ¢Í§
»ÃЪҡ×ÕèµÒ¹ÕéÍÂÙèã¹»ÃÐà—È—Õè¡ÓÅѧ¾Ñ²¹Ò
áÅÐÊͧ
ã¹ÊÒÁ¢Í§¼Ùé»èÇÂÍÂÙè㹗ÇÕ»àÍàªÕ
Â
ÃÇÁ¶Ö§¼Ùé»èǨӹǹ
ÁÒ¡

—ÕèäÁè¡Ô¹ÂÒµÒÁ—ÕèᾗÂì¡Ó˹´
â´ÂÁÒ¡ÁÑ¡¡Ô¹ÂÒ
à¾Õ§ 1-2 à´×͹áÅéÇËÂØ´àÁ×èÍàËç¹ÇèÒÍÒ¡ÒôբÖé
¹
à»ç
¹
¼ÅãËéàª×éÍÇѳâäÁÕ¡Òô×éÍÂÒÁÒ¡¢Öé¹àÃ×èÍÂ
æ
áÁéÇèһѨ¨ØºÑ
¹
ᾗÂì¨ÐãËé¡ÒÃÃÑ¡ÉÒÇѳâä´éÇÂÂÒ¾ÃéÍÁ¡Ñ¹¶Ö§ 4 ª¹Ô
´
áµèàª×é͗ÕèÁÕ¡Òô×éÍÂÒËÅÒ¢¹Ò¹ (multi-drug
resistance) ÁÒ¡¢Öé¹àªè¹à´ÕÂÇ¡Ñ
¹
ÂÔ觡ÇèÒ¹ÕéàÁ×èͻվ.È.
2535 ÂѧÁÕÃÒ§ҹ¡ÒÃÃкҴ¢Í§Çѳâä
—Õèàª×éÍ´×éÍÂÒµè
Í
ÂÒËÅÒ¢¹Ò¹ã¹ÊËÃÑ°ÍàÁÃÔ¡Ò
¨¹Í§¤ì¡ÒÃ͹ÒÁÑÂâÅ¡
µéͧ»ÃСÒÈàÁ×èÍà´×͹àÁÉÒ¹
¾.È. 2536 ÇèÒÇѳâä
à»ç¹»ÑËÒ©Ø¡à©Ô¹´éÒ¹ÊØ¢ÀÒ¾ÃдѺâÅ¡4
»ÃÐà—Èä—ÂÁÕ
¼Ùé»èÇÂÇѳâäªØ¡ªØÁÊÙ§à»ç
¹
Íѹ´Ñº—Õè 12 ¢Í§âÅ¡
¤×
Í
ÁÕÍѵÃÒ»èÇ 179 ¤¹µè
Í
»ÃЪҡà 1 áʹ¤¹
áÅлÃÐà—Èä—Âä´é¶Ù¡¨Ñ´à»ç¹ 1
ã¹ 6 »ÃÐà—Ȣͧ—ÇÕ»àÍàªÕ—ÕèÁըӹǹ¼Ùé»èÇÂÇѳâä
ÊÙ§ÊØ´Ãͧ¨Ò¡¨Õ
¹
ÍÔ¹à´Õ
Â
ÍԹⴹÕà«Õ
Â
ºÑ§¤ÅÒà—È
áÅÐ
àÇÕ´¹ÒÁ
¨Ó¹Ç¹¼Ùé»èÇÂÇѳâä—Õè¢Ö鹗ÐàºÕ¹ãËÁèàÃÔè
Á
áÊ´§á¹Çâ¹éÁà¾ÔèÁ¢Öé¹ËÅѧ»Õ¾.È. 2534 â´ÂÁÒ¡—ÕèÊØ
´
ã¹ÀÒ¤à˹×͵͹º¹
µÒÁ´éÇÂÀÒ¤¡ÅÒ§
ÀÒ¤µÐÇѹÍÍ¡
à©Õ§à˹×
Í
áÅÐÀÒ¤ãµé»Ñ¨¨ÑÂÊӤэ—Õè—ÓãËéÇѳâäá¾Ãè
¡ÃШÒÂä´éàÃç
Ç
ä´éá¡è¤ÇÒÁáÍÍÑ´¢Í§»ÃЪҡÃËÃ×
Í
ªØÁª¹

»ÃЪҡÃäǵèÍàª×é
Í
àªè
¹
»ÃЪҡÃÁÕÀÙÁÔ¤ØéÁ¡Ñ
¹
µè
Ó
à»ç¹àÍ´ÊìËÃ×Íà´ç¡«Öè§ÃкºÀÙÁÔ¤ØéÁ¡Ñ¹Âѧ—Ó§Ò¹äÁè´Õ¾Í
¨ÐäǵèÍ¡ÒõԴàª×é
Í
àª×éÍÇѳâä´×éÍÂÒà»ç¹»ÑËÒ˹Ö觗Õè
—ÓãËéÇѳâäÃкҴà¾ÔèÁ¢Öé
¹
¨Ò¡¡ÒÃÊÓÃǨà©ÅÕè—Ñè
Ç
»ÃÐà—ȾºÃéÍÂÅÐ 2.53 àÁ×èͻվ.È. 2539-2541 áµè
ÊÙ§¢Öé¹ã¹—éͧ—Õè—ÕèÁÕ¡ÒÃÃкҴ¢Í§¡ÒõԴàª×éÍàÍ´ÊìÊÙ
§
àªè
¹
¨Ñ§ËÇÑ´àªÕ§ÃÒÂ
áÅСÃØ§à—¾Ï5

»Õ—Õè 19 ©ºÑº—Õè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
ÇÔÇѲ¹Ò¡Òâͧ¡ÒÃÃÑ¡ÉÒÇѳâä
¡è͹¡ÒÃÃÑ¡ÉÒ㹻Ѩ¨ØºÑ
¹
ÁÕ¡Ò×´ÅͧÃÑ¡ÉÒ
Çѳâä´éÇÂÇÔ¸ÕµèÒ§æ
àªè
¹
¡ÒÃÍÍ¡¡ÓÅѧ¡ÒÂ
¡Òù͹
¹Ôè§äÁèà¤Å×è͹äËÇ
¡ÒÃà»ÅÕ蹶èÒÂàÅ×Í´
¡ÒéմâÅËÐ˹Ñ
¡
µèÒ§æ
àªè
¹
—ͧ¤Ó (gold) ¡Ò×ÓãËéà¡Ô´ÅÁÃÑèÇ㹪èͧ
àÂ×èÍËØéÁ»Í´ËÃ×Í㹪èͧàÂ×èÍËØéÁ—éͧ
¡ÒüèҵѴÅÍ¡àÂ×è
Í
ËØéÁ»Í´
à»ç¹µé
¹
«Öè§äÁè»ÃÐʺ¼ÅÊÓàÃç¨ã¹¡ÒÃÃÑ¡ÉÒ6
¡ÒÃÃÑ¡ÉÒâäÇѳâä
ÁÕ¡ÒþѲ¹ÒÁÒ¨Ò¡ËÅÒÂ
¡ÒÃÈÖ¡ÉÒà»ç¹àÇÅÒÁÒ¡¡ÇèÒ 50 »ÕàÃÔèÁµÑé§áµè»Õ¾Ø—¸ÈÑ¡ÃÒª
2481 Rich áÅÐ Follis7 ¨Ò¡ÁËÒÇԗÂÒÅѨÍËì
¹
Î;¡Ô¹Êì (Johns Hopkins University) —´Åͧãªé
ÂÒ«ÑÅ¿Ò¹ÔÅÒäÁ´ì (sulfanilamide) ¢¹Ò´ÊÙ
§
¾ºÇè
Ò
ÊÒÁÒöÂѺÂÑé§àª×éÍÇѳâäã¹Ë¹ÙµÐàÀҗ´Åͧä´éµè
Í
ÁÒ Schatz áÅÐ Waksman ÃÔàÃÔèÁãªéÂÒ streptomycin
ã¹Á¹ØÉÂì¤ÃÑé§áá㹻վ.È. 24878 â´ÂÊ¡Ñ´¨Ò¡àª×éÍÃÒ
Streptomyces griseus µèÍÁÒ»Õ¾.È. 2489 â´Â the
British Medical Research Council (BMRC)
—´ÅͧãªéÂÒ streptomycin ÃèÇÁ¡Ñº¡Òù͹¹Ôè§äÁè
à¤Å×è͹äËÇà»ÃÕºà—Õº
¡Ñº¡Òù͹¹Ôè§äÁèà¤Å×è͹
äËÇÍÂèÒ§à´ÕÂÇ
㹡ÒÃÃÑ¡ÉÒÇѳâäàÂ×èÍËØéÁÊÁͧáÅÐ
Çѳâä»Í´
¾ºÇèÒà¾ÔèÁÍѵÃÒ¡ÒÃÃÍ´ªÕÇÔµä´éã¹ÃÐÂÐÊÑé
¹
ÍÂèÒ§äáç´ÕÁÕ¡Òô×éÍÂÒÍÂèÒ§ÃÇ´àÃç
Ç
¾ºÇèÒÃéÍÂÅÐ 92 ¢Í§
¼Ùé»èÇ—ÕèãªéÂÒ streptomycin ª¹Ô´à´ÕÂǹҹ 3 à´×͹
ÂѧÁÕ¼Åà¾ÒÐàª×éͨҡàÊÁËÐà»ç¹ºÇ¡9 ã¹»Õà´ÕÂÇ¡Ñ

¹
Lehmann ¨Ò¡ÊÇÕà´¹10 ¤é¹¾º¾ÒÃÒÍÐÁÔ⹫ÒÅÔÊÔÅÔ
¡
áÍÊÔ´ (para-aminosalicylic acid, PAS) à¹×èͧ
¨Ò¡¾ºÇèÒ˹Öè§ã¹ÊÒÁ¢Í§¼Ùé»èÇ—Õèãªé PAS ª¹Ô´à´ÕÂÇ
¹Ò¹ 4 à´×͹
ÂѧÁÕ¼Åà¾ÒÐàª×éͨҡàÊÁËÐà»ç¹ºÇ¡
ã¹
»Õ¾.È. 2491 ¨Ö§àÃÔèÁÁÕ¡ÒÃãªéÂÒ streptomycin ¤Ùè¡ÑºÂÒ
PAS â´ÂÊÒÁÒö—ÓãËé¼ÅàÊÁËÐà»ç¹Åºä´éàÁ×èÍ¡ÒÃ
ÃÑ¡ÉÒ¹Ò¹ 4 à´×͹11 ÍÂèÒ§äáçµÒÁ
Âѧ¾º¡Òô×é
Í
streptomycin ä´éà¡×ͺÃéÍÂÅÐ 10 áÁéÇèÒãªéÃèÇÁ¡Ñº PAS
»Õ¾.È. 2495 ÊÒÁºÃÔÉїÂÒ
ä´éá¡è Hoffman
LaRoche, ER. Squibb & Sons áÅÐ Bayer àÃÔè
Á
¹ÓÂÒ isoniazid ÁÒãªé«Ö觾ºÇèÒ»ÃÐÊԗ¸ÔÀÒ¾´ÕÁÒ¡
ÃÒ¤Ò
äÁèᾧ
ÃÇÁ—Ñ駼ŢéÒ§à¤Õ§µèÓÍÕ¡´éÇÂ
áÅÐàÁ×è͹ÓÂÒ
isoniazid ãªé¤Ùè¡Ñº streptomycin ¾ºÇèÒ»ÃÐÊԗ¸ÔÀÒ¾
à˹×Í¡ÇèÒ streptomycin áÅÐ PAS µèÍÁÒ»Õ¾.È
2498-2499 ÁÕÍѵÃÒ¡Òô×éÍ streptomycin ÃéÍÂÅÐ 2.5,
PAS ÃéÍÂÅÐ 2.6, isoniazid ÃéÍÂÅÐ 1.3 ¨Ö§àÃÔèÁãªéÂÒ
ÃèÇÁ¡Ñ¹ÁÒ¡¡ÇèÒ 2 ª¹Ô
´
¹Ò¹¶Ö§ 24 à´×͹
à¾×èÍá¡éä¢
àÃ×èͧ¡Òô×éÍÂÒ
Pyrazinamide (PZA) ¶Ù¡¤é¹¾º»Õ¾.È. 2495
àªè¹à´ÕÂǡѺÂÒ isoniazid â´Â Lederle Research
Laboratories ã¹»Õ¾.È. 2503 ÁÕ¡Òä鹾º rifampicin
«Öè§à»ç¹ÂÒÃѺ»ÃЗҹ—ÕèÁÕė¸
ìÔ¦èÒàª×éÍÇѳâä—Õè
ÁÕ
»ÃÐÊԗ¸ÔÀÒ¾
—ÓãËéÊÒÁÒöŴÃÐÂÐàÇÅÒ¡ÒÃÃÑ¡ÉÒ¨Ò¡
18-24 à´×͹
àËÅ×Íà¾Õ§ 6 à´×͹
â´ÂäÁèà¾Õ§áµèËÒÂ
¢Ò´
áµèÂѧ»éͧ¡Ñ¹¡ÒáÅѺà»ç¹«éӢͧâä12 ÊèǹÂÒ
Ethambutol (EMB) ¶Ù¡¤é¹¾º»Õ¾.È. 2504 ¨ÐàËç
¹
ä´éÇèÒÂؤ—ͧ¢Í§¡ÒäԴ¤é¹ÂÒÃÑ¡ÉÒÇѳâäÍÂÙè㹪èǧ
—ÈÇÃÃɹÕé
㹨ѧËÇÑ´ Madras ã¹»ÃÐà—ÈÍÔ¹à´Õ
Â
ÁÕ¡ÒÃ
ÃÔàÃÔèÁ¡ÒÃÃÑ¡ÉÒ¼Ùé»èÇÂÇѳâä—ÕèºéÒ¹
¾ºÇèÒä´é¼Åà»ç¹—Õè¹è

Ò
¾Íã¨
áÅÐäÁèà¾ÔèÁ¡ÒõԴàª×éͧ͢¤¹ã¹¤Ãͺ¤ÃÑǗÕèÍÂÙè
ÃÇÁ¡Ñº¼Ùé»èÇ´éÇÂ
ÍÂèÒ§äáç
´ÕµèÍÁÒÁÕ¡ÒÃãªéá¹Ç¤ÇÒÁ
¤Ô´ directly observed therapy (DOTS) ã¹»Õ¾.È.
2501 à¾×èÍãËé¼Ùé»èÇÂÃѺ»ÃЗҹ¤Ãº¶éǹÁÒ¡¢Öé
¹
ÂҗÕèÁÕ»ÃÐÊԗ¸ÔÀҾ㹡ÒæèÒàª×éÍÇѳâäã¹
»Ñ¨¨ØºÑ
¹
áÅÐä´éÃѺ¡ÒÃÂÍÁÃѺâ´Â
ͧ¤ì¡ÒÃÍÒËÒÃáÅÐ
ÂÒ (Food and Drug Administration, FDA) ¢Í§
ÊËÃÑ°ÍàÁÃÔ¡Ò
àªè¹ isoniazid, pyrazinamide,
rifampicin, ethambutol, rifapentine, cycloserine,
ethionamide, capreomycin, PAS áÅÐ
streptomycin ÊèǹÂҗÕèäÁèä´éÃѺ¡ÒÃÂÍÁÃѺâ´Âͧ¤ì¡ÒÃ
ÍÒËÒÃáÅÐÂÒáµè¼ÙéàªÕèÂǪҍá¹Ð¹ÓãËéãªéä´éàªè
¹
rifabutin aminoglycosides (amikacin,
kanamycin), fluoroquinolones (ciprofloxacin,
moxifloxacin, levofloxacin) (µÒÃÒ§—Õè 1)

¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
µÒÃÒ§—Õè 1. áÊ´§ÂÒÃÑ¡ÉÒÇѳâä—ÕèÁÕãªé㹻Ѩ¨ØºÑ¹ã¹»ÃÐà—ÈÊËÃÑ°ÍàÁÃÔ¡Ò
First-line drugs
Isoniazid
Rifampin
Rifapentine
Rifabutin*
Ethambutol
Pyrazinamide
Streptomycin
Second-line drugs
Cycloserine
Ethionamide
Levofloxacin*
Moxifloxacin*
Gatifloxacin*
Para-aminosalicylic acid
Amikacin/kanamycin*
Capreomycin
* äÁèä´éÃѺ¡ÒÃÂÍÁÃѺ¨Ò¡Í§¤ì¡ÒÃÍÒËÒÃáÅÐÂÒ (Food and Drug Administration, FDA)
ËÅÑ¡¡ÒÃÃÑ¡ÉÒÇѳâäẺÃÐÂÐÊÑé¹ (shortcourse
chemotherapy) ÃÒ§ҹ¤ÃÑé§ááã¹á¶º
áÍ¿ÃÔ¡ÒµÐÇѹÍÍ¡13 â´Âà»ÃÕºà—ÕºÃÐÂÐàÇÅÒ¡ÒÃ
ÃÑ¡ÉÒ 6 à´×͹
´éÇ streptomycin áÅÐ isoniazid,
streptomycin, isoniazid áÅÐ rifampicin,
streptomycin, isoniazid áÅÐ pyrazinamide,
streptomycin, isoniazid and thioacetazone ¡Ñ
º
ÃÐÂÐàÇÅÒ¡ÒÃÃÑ¡ÉÒ 18 à´×͹
´éÇÂÂÒ isoniazid áÅÐ
thioacetazone ¼Å¡ÒÃÃÑ¡ÉÒ¾ºÇèÒ¡ÒÃãªéÂÒ 3 ª¹Ô
´
¤×Í streptomycin, isoniazid áÅÐ rifampicin ÊÒÁÒö
à»ÅÕè¹àÊÁËÐà»ç¹Åº—ÕèÃÐÂÐàÇÅÒÊÔé¹ÊØ´¡ÒÃÃÑ¡ÉÒ
áÅÐ
¡ÒÃÍѵÃÒ¡ÅѺà»ç¹«éÓà¾Õ§ÃéÍÂÅÐ 314
㹻Ѩ¨ØºÑ¹¤ÇÒÁàËç¹ã¹àÃ×èͧ¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
—ÕèàËÁÒÐÊÁ—ÕèÊØ´¨ÐµÃ§¡Ñ¹—ÑèÇâÅ¡
¡ÅèÒǤ×
Í
ÁÕá¹Ç—Ò§
àʹÍá¹Ð
â´Â¡ÅØèÁ¼ÙéàªÕèÂǪҍ㹻ÃÐà—È—Õè¾Ñ²¹ÒáÅé
Ç
àªè
¹
ÊËÃÑ°ÍàÁÃÔ¡Ò (American Thoracic Society

¾.È. 2537) ¡ÑºÊËÃÒªÍҳҨѡà (British Thoracic
Society ¾.È. 2540) áÅЗÕèàʹÍá¹Ðâ´Âͧ¤ì¡ÒùҹÒ
ªÒµÔä´éá¡èͧ¤ì¡ÒÃ͹ÒÁÑÂâÅ¡ (WHO Tuberculosis
Unit ¾.È. 2540) áÅÐ International Union Against
Tuberculosis and Lung Disease (IUATLD ¾.È.
2540) Êͧͧ¤ì¡ÃËÅѧà»ç¹á¹Ç—Ò§—ÕèÁØè§à¹é¹ÊÓËÃÑ
º
»ÃÐà—È—Õè¡ÓÅѧ¾Ñ²¹Ò—ÕèÂѧÁÕÇѳâäªØ¡ªØ
Á
©Ð¹Ñ鹨֧¡ÅèÒÇ
ä´éÇèÒ¡ÒÃÃÑ¡ÉÒÃÐÂÐÊÑ鹗Õèãªé㹻Ѩ¨ØºÑ¹à»ç¹ÃкºÂÒÃдÑ
º
¹Ò¹ÒªÒµÔËÃ×ÍÃдѺâÅ¡
—ÕèÁÕ»ÃÐÊԗ¸ÔÀÒ¾áÅÐ
»ÃÐÊԗ¸Ô¼Å´Õ—ÕèÊØ
´
—Õè¨ÐÃÑ¡ÉÒ¼Ùé»èÇÂÇѳâäãËéËÒÂä´é
à¡×ͺÃéÍÂÅÐ 100 ¶éÒ¼Ùé»èÇÂä´éÃѺÂÒÊÁèÓàÊÁͤú¶éǹ
ÂÒÃÑ¡ÉÒÇѳâä15,16,17,18
äÍâ«ä¹ÍÐÊÔ´ (isoniazid)

»Õ—Õè 19 ©ºÑº—Õè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
ÂÒäÍâ«ä¹ÍÐÊÔ´ (isoniazid) àÃÔèÁ¹ÓÁÒãªéã¹
»Õ¾.È. 2495 ãªéÃÑ¡ÉҗÑ駡ÒõԴàª×éÍËź«è͹áÅСÒÃ
µÔ´àª×éÍẺáÊ´§ÍÒ¡ÒÃ
Í͡ė¸ìԢѴ¢ÇÒ§¡ÒÃÊÃéÒ§¡Ã´
äÁâ¤ÅÔ¡ (mycolic acid)19 ã¹¢Ñ鹵͹—Õèµéͧãªé
ÍÍ¡«Ôਹ
«Ö觡ôäÁâ¤ÅÔ¡à»ç¹¡Ã´ä¢Áѹ¢¹Ò´ÂÒÇ«Öè
§
Êèǹ»ÃСͺ¢Í§¼¹Ñ§à«ÅÅì (ÀÒ¾—Õè 1) ÂÒäÍâ«ä¹
ÍÐÊÔ´¦èÒàª×é͗Õè¡ÓÅѧáºè§µÑÇä´éÍÂèÒ§ÃÇ´àÃç
Ç
ºÃÔËÒÃÂÒ
â´Â¡ÒÃÃѺ»ÃЗҹ
ÍÒ¨ãªé©Õ´à¢éÒ¡ÅéÒÁà¹×éÍËÃ×Íà¢é
Ò
ËÅÍ´àÅ×Í´´Óä´é¢¹Ò´»¡µÔ 3-5 ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹Ñ
¡
µÑÇ 1 ¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
¢¹Ò´ÂÒÊÙ§ÊØ´ 300 ÁÔÅÅÔ¡ÃÑÁµè
Í
ÇÑ
¹
ÃдѺÂÒÊÙ§ÊØ´ 1-2 ªÑèÇâÁ§
ËÅѧÃѺ»ÃЗҹ
ÃдÑ
º
ÂÒÍÒ¨¶Ù¡´Ù´«ÖÁ¹éÍÂŧËÒ¡ÃѺ»ÃЗҹÃèÇÁ¡Ñº¹éÓµÒÅ
¡ÅÙâ¤ÊËÃ×ÍáÅ¡âµÊ
ÂÒ¼èÒ¹à¢éÒÃкº»ÃÐÊҗÊèǹ¡ÅÒ§
ä´é
´Õ¶Ù¡¡Ó¨Ñ´—Ò§µÑºâ´ÂÇÔ¸ÕÍÐ૵ÔàŪÑè¹ (acetylation)
â´ÂäÁèÁÕ¤ÇÒÁÊÑÁ¾Ñ¹¸ìÃÐËÇèÒ§ÃдѺÂÒã¹àÅ×Í´áÅСÒÃ
à»ç¹¾Ôɵè͵Ñ
º
ÀÒ¾—Õè 1 áÊ´§µÓá˹觡ÒÃÍ͡ė¸ìԢͧÂÒ20

¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
¼Å¢éÒ§à¤Õ§¢Í§ÂÒäÍâ«ä¹ÍÐÊÔ
´
—ÓãËéÃдÑ
º
»ÃÐÁÒ³ÃéÍÂÅÐ 1 µèÍ»Õ23 ¨Ò¡¡ÒÃÈÖ¡ÉҢͧ Steele
à͹ä«ÁìÍÐÁÔ⹗ÃÒ¹à¿ÍàÃÊ (aminotranferases) à¾Ôè
Á
ÊÙ§¢Öé¹ä´é¶Ö§ 5 à—èҢͧ¤èÒ»¡µÔâ´ÂäÁèÁÕÍÒ¡Ò×ҧ¤ÅÔ¹Ô
¡
¾º»ÃÐÁÒ³ÃéÍÂÅÐ 10-20 áÅÐÊÒÁÒö¡ÅѺŧÊÙèÃдÑ
º
»¡µÔä´éàͧ
â´ÂäÁèµéͧËÂØ´ÂÒ
µÑºÍÑ¡àʺ¨Ò¡ÂÒäÍâ«ä¹ÍÐÊÔ´á¡ÂÒ¡¨Ò¡µÑ
º
ÍÑ¡àʺ¨Ò¡àª×éÍäÇÃÑ
Ê
—Ñ駨ҡÍÒ¡ÒÃáÅоÂÒ¸ÔÇԗÂҢͧ
µÑ
º
¨Ò¡ÃÒ§ҹ¢Í§ Black áÅФ³Ð21 ÈÖ¡ÉÒ¼Ùé»èÇÂ
114 ¤¹
¾ºÇèÒÁÒ¡¡ÇèÒ¤ÃÖè§ÁÕÍÒ¡Ò×ҧÃкº—Ò§à´Ô
¹
ÍÒËÒ×ÕèäÁè¨Óà¾ÒÐà¨ÒШ§
ÍÒ¡ÒäÅéÒµԴàª×éÍäÇÃÑ
Ê
¾º»ÃÐÁÒ³ÃéÍÂÅÐ 35 ËÅѧ¨Ò¡¹Ñé¹ËÅÒÂÇѹ¨¹¶Ö§ËÅÒÂ
ÊÑ»´ÒËì¨Ö§ÁÕÍÒ¡ÒÃàËÅ×ͧµÒÁÁÒ
ÊèǹÍÒ¡ÒÃàËÅ×ͧ—Õèà»ç
¹
ÍÒ¡ÒùӾºá¤èÃéÍÂÅÐ 10 â´Âà¡×ͺÃéÍÂÅÐ 50 ¾ºã¹
ªèǧ 2 à´×͹áá¢Í§¡ÒÃÃѺ»ÃЗҹÂÒ
áµèºÒ§ÃÒÂÍÒ¨
¾ºä´é¹Ò¹¶Ö§ 14 à´×͹
¨Ò¡ÃÒ§ҹ»Õ¾.È. 251522 ¾º¼Ùé
àÊÕªÕÇÔµ 2 ÃÒÂ
µèÍÁÒÈÙ¹Âì¤Çº¤ØÁáÅлéͧ¡Ñ¹âäµÔ´µè
Í
ÃÒ§ҹÇèÒÁÕ
¼Ùé»èǵѺÍÑ¡àʺ¨Ò¡ÂÒäÍâ«ä¹ÍÐÊÔ
´
áÅФ³Ð24 (µÒÃÒ§—Õè 2) ã¹»Õ¾.È. 2503-2523 ¾ºÇè
Ò
ÍѵÃÒ¡ÒÃà¡Ô´µÑºÍÑ¡àʺÃéÍÂÅÐ 0.6 Êèǹ Nolan áÅÐ
¤³Ð25 —Ó¡ÒÃÊÓÃǨ 7 »Õ¾ºà¾Õ§ÃéÍÂÅÐ 0.1-0.3 ÍÂèÒ§
äáç
´Õ¾ºµÑºÍÑ¡àʺä´éÁÒ¡¢Ö鹶֧ÃéÍÂÅÐ 2.7 ¶éÒãªéÃèÇÁ
¡ÑºÂÒäÃá¿Á¾Ô«Ô¹ (rifampicin) ¹Í¡¨Ò¡¹ÕéÂѧ¾ºà¾Ôè
Á

¢Öé¹ã¹¼ÙéÊÙ§ÍÒÂØâ´Â੾ÒÐÍÂèÒ§ÂÔè§ÍÒÂØÁÒ¡¡ÇèÒ 65 »Õ
¾º»ÃÐÁÒ³ÃéÍÂÅÐ 4.6 âäµÑºáÅмÙé´×èÁÊØÃÒà»ç¹»ÃШÓ
¾º»ÃÐÁÒ³ÃéÍÂÅÐ 2.6 »Ñ¨¨ÑÂàÊÕè§Í×è¹æ
ä´éá¡èˍÔ
§
µÑ駤ÃÃÀ
ìËÃ×ͼÙé—ÕèÃѺ»ÃЗҹÂҗÕè¡ÃеØ鹡Ò×ӧҹ¢Í§
ä«âµâ¤ÃÁ¾Õ (cytochrome P 450) àªè
¹
ÂҡѹªÑ¡ä´
áŹµÔ¹ (dilantin) ´Ñ§¹Ñ鹤ÇÃãªéÂÒ´éǤÇÒÁÃÐÁÑ´ÃÐÇÑ
§
ËÁÑè¹µÃǨ¡Ò×ӧҹ¢Í§µÑº—Ø¡à´×͹ËÃ×ÍàÁ×èÍàÃÔèÁÁÕ
ÍÒ¡ÒÃ
ËÂØ´ÂÒàÁ×èÍÃдѺà͹ä«ÁìÍÐÁÔ⹗ÃÒ¹à¿ÍàÃÊ
(aminotranferases) à¾ÔèÁÊÙ§¢Öé¹ÁÒ¡¡ÇèÒ 3-5 à—èҢͧ
¤èÒ»¡µÔ
µÒÃÒ§—Õè 2 áÊ´§¡ÒÃà¡Ô´µÑºÍÑ¡àʺ¨Ò¡ÂÒäÍâ«ä¹ÍÐÊÔ´24
âä¢Í§àÊé¹»ÃÐÊҗÊèǹ»ÅÒÂÊÑÁ¾Ñ¹¸ì¡Ñº¢¹Ò´
¢Í§ÂÒäÍâ«ä¹ÍÐÊÔ
´
¾º¹éÍ¡ÇèÒÃéÍÂÅÐ 0.2 ¶éÒãªéÂÒ
¢¹Ò´»¡µÔÁÑ¡à¡Ô´ã¹¼Ùé—ÕèÁջѨ¨ÑÂàÊÕ觵èÍ¡ÒÃà¡Ô´âä¢Í§
àÊé¹»ÃÐÊҗÊèǹ»ÅÒÂÍÂÙèà´Ô
Á
¼Ùé—Õè¢Ò´ÇÔµÒÁÔ
¹
´×èÁÊØÃÒ
àºÒËÇÒ¹
âääµ
ˍԧµÑ駤ÃÃÀìËÃ×ÍàÅÕ駺صôéǹéÓ¹Á
¡ÒÃãËéÇÔµÒÁÔ¹ºÕË¡ (pyridoxine) ¢¹Ò´ 25 ÁÔÅÅÔ¡ÃÑ
Á
µèÍÇÑ
¹
ªèÇ»éͧ¡Ñ¹¡ÒÃà¡Ô´ä´é
ÁÕÃÒ§ҹ¡ÒÃà¡Ô´»‾Ô¡ÔÃÔÂҵͺʹͧ¤ÇÒÁäǵè
Í
ÂÒ
àªè
¹
ä¢é¼×蹤Ñ
¹
ʵÕàǹ
¨ÍËì¹Êѹ (Stevens Johnson
syndrome) àÁç´àÅ×Í´¢Òǵè
Ó
àÁç´àÅ×ʹᴧᵡ§èÒÂ
»Ç´¢é
Í
ªÑ
¡
ÍÒ¡Ò×ҧÃкº»ÃÐÊҗ
ËÃ×ÍÅѡɳÐ
¤ÅéÒÂâäÅÙ»Ñ
Ê

¾ºá͹µÔºÍ´ÕéµèÍÀÙÁÔ¤ØéÁ¡Ñ¹µÑÇàͧ (antinuclear
antibodies) ä´é¶Ö§ÃéÍÂÅÐ 20 ¾º¡ÒÃà¡Ô´ÍÒ
¡ÒÃâäÅÙ»ÑÊä´é¹éÍ¡ÇèÒÃéÍÂÅÐ 1 áµèËÒ¡à¡Ô´µéͧËÂØ
´
Âҗѹ—Õ

»Õ—Õè 19 ©ºÑº—Õè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
ºÒ§ÃÒ§ҹ¾ºÇèÒËÒ¡ÃѺ»ÃЗҹÍÒËÒ×ÕèÁÕÊèǹ
»ÃСͺ¢Í§âÁâ¹àÍÁÕ¹ (monoamine) àªè
¹
äǹ
ìÍÒ¨
—ÓãËéÃдѺâÁâ¹àÍÁÕ¹ÊÙ§¨¹à¡Ô´ÍÒ¡ÒÃà»ç¹¾ÔÉä´é
»‾Ô¡ÔÃÔÂҡѺÂÒÍ×è
¹
ä´éá¡èà¾ÔèÁÃдѺÂҡѹªÑ
¡
¿Õ¹ÔÅâµÍÔ¹ (phenytoin) áÅÐ
¤ÒºÒÁÒ«Õ»Ô
¹
(carbamazepine) ´Ñ§¹Ñé
¹
ÍÒ¨µéͧµÃǨÃдѺÂÒ¡Ñ
¹
ªÑ¡ã¹àÅ×Í´à¾×èÍ»ÃѺ¢¹Ò´ÂÒ
äÿÒäÁ«Ô¹ (rifamycins)
äÿÒäÁ«Ô
¹
»ÃСͺ´éÇÂ
äÃá¿Á»Ô
¹
(rifampin) äÿҺٵԹ (rifabutin) áÅÐ
äÿÒà¾ç
¹
µÔ¹ (rifapentine) à»ç¹ÂÒµÑÇÊӤэ㹡ÒÃÃÑ¡ÉÒÇѳâä
—Ø¡ÃٻẺáÅШÓà»ç¹µÅÍ´ÃÐÂÐàÇÅÒ¡ÒÃÃÑ¡ÉÒ
ÍÍ¡
ė¸ìԢѴ¢ÇÒ§¡ÒÃÊÃéÒ§äÃ⺹ÔǤÅÕÍÔ¤áÍÊÔ´ (RNA)
ã¹¢Ñ鹵͹ transcription â´Â¨Ñº¡ÑºÊèǹີéÒ (.subunit
of RNA polymerase) (ÀÒ¾—Õè 1) ¦èÒàª×é
Í
Çѳâä—Ñ駢³Ð—Õè¡ÓÅѧáºè§µÑÇÍÂèÒ§ÃÇ´àÃçÇáÅÐàª×é͗Õè
ʧºÍÂÙ袹Ҵ¢Í§äÃá¿Á»Ô¹ã¹¼Ùéãˍè 10 ÁÔÅÅÔ¡ÃÑ
Á
µè͹éÓ˹ѡµÑÇ 1 ¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
¢¹Ò´ÊÙ§ÊØ´ 600
ÁÔÅÅÔ¡ÃÑÁµèÍÇÑ
¹
äÃá¿Á»Ô¹—ÓãËéà»ÅÕè¹ÊÕÊÒäѴËÅÑè
§
µèÒ§æ¢Í§ÃèÒ§¡ÒÂ
àªè
¹
¹éÓµÒ
à˧×è
Í
»ÑÊÊÒÇÐ

ËÃ×ÍáÁé
áµèÊդ͹ᗤàŹÊ
ì¼Å¢éÒ§à¤Õ§Í×è¹æ
ä´éá¡è¼×蹤Ñ
¹
(ÃéÍÂÅÐ 6) ¤Å×è¹äÊé—éͧàÊÕ
Â
»Ç´—éͧ
ÍÒ¨¾ºÃдÑ
º
ºÔÅÔÃÙºÔ¹ÊÙ§¢Öé¹ä´éªÑèǤÃÒÇ (ÃéÍÂÅÐ 0.6) «Öè§ÍÒ¡ÒÃàËÅè
Ò
¹ÕéÁÑ¡äÁè¨Óà»ç¹µéͧËÂØ´ÂÒ
ÂÒäÃá¿Á»Ô¹—ÓãËéà¡Ô´µÑ
º
ÍÑ¡àʺ¹éÍÂÁÒ¡
à¡×ͺÃéÍÂÅÐ 0 ËÒ¡ãªéÃèÇÁ¡ÑºÂÒäÍ
â«ä¹ÍÐÊÔ
´
¨Ðà¾ÔèÁ¡ÒÃà¡Ô´µÑºÍÑ¡àʺä´é¶Ö§ÃéÍÂÅÐ 2.7
áµèËÒ¡ãªéÃèÇÁ¡ÑºÂÒÍ×蹗ÕèäÁèãªèäÍâ«ä¹ÍÐÊÔ
´
¨Ðà¾ÔèÁ¡ÒÃ
à¡Ô´µÑºÍÑ¡àʺÃéÍÂÅÐ 1.1
ËÒ¡ãªéÂÒäÃá¿Á»Ô¹à¡Ô¹¢¹Ò´—Õè¡Ó˹´
ËÃ×Íãªé
ÂÒẺ 2-3 ¤ÃÑ駵èÍÊÑ»´ÒË
ìÍÒ¨à¡Ô´ÍÒ¡ÒäÅéÒÂä¢éËÇÑ
´
ãˍèÍÔ¹¿ÙàÍ繫èÒ (influenza) ä´é»ÃÐÁÒ³ÃéÍÂÅÐ 0.4
0.7 ¤×
Í
ÁÕä¢é˹ÒÇÊÑè
¹
»Ç´ÈÕÃÉÐ
»Ç´àÁ×è͵ÒÁµÑ
Ç
»Ç´¢é
Í
ÍÒ¡ÒÃàËÅèÒ¹ÕéÁÑ¡à¡Ô´ËÅѧÃѺ»ÃЗҹÂÒ 1-2
ªÑèÇâÁ§
áÅÐÍÒ¨¹Ò¹¶Ö§ 8 ªÑèÇâÁ§
àª×èÍÇèÒà»ç¹»‾Ô¡ÔÃÔÂÒ
µÍºÊ¹Í§—Ò§ÃкºÀÙÁÔ¤ØéÁ¡Ñ
¹
¾ºã¹¼Ùé—ÕèÃѺ»ÃЗҹÂÒ
à»ç¹ªèǧæÁÒ¡¡ÇèÒ¡ÒÃÃѺ»ÃЗҹÂҗءÇÑ
¹
â´Âà¡Ô´ä´é
—Ø¡àÇÅÒã¹ÃÐËÇèÒ§¡ÒÃÃÑ¡ÉÒ
áµèÁÑ¡¾ºËÅѧ¨Ò¡ÃÑ
º
»ÃЗҹä»áÅéÇ»ÃÐÁÒ³ 3-6 à´×͹ Grosset áÅÐ
¤³Ð26 à»ÃÕºà—Õº¡ÒÃÃѺ»ÃЗҹÂÒäÃá¿Á»Ô
¹

¾ºÇè
Ò
¶éÒÃѺ»ÃЗҹ¢¹Ò´ 1200-1800 ÁÔÅÅÔ¡ÃÑ
Á
µèÍÊÑ»´ÒË
ì
à¡Ô´ÍÒ¡ÒäÅéÒÂÍÔ¹¿ÙàÍ繫èÒÃéÍÂÅÐ 35-57 ¶éÒÃѺ»ÃЗҹ
¢¹Ò´ 900 ÁÔÅÅÔ¡ÃÑÁµèÍÊÑ»´ÒË
ìà¡Ô´ÍÒ¡ÒäÅéÒÂÍÔ¹¿ÙàÍç
¹
«èÒÃéÍÂÅÐ 22-31 áÅÐà¡Ô´à¾Õ§ÃéÍÂÅÐ 10 ¶éÒÃѺ»ÃЗҹ
¢¹Ò´ 600 ÁÔÅÅÔ¡ÃÑÁµèÍÊÑ»´ÒË
ì
»‾Ô¡ÔÃÔÂҵͺʹͧ—Ò§ÀÙÁÔ¤ØéÁ¡Ñ
¹
àªè
¹
à¡Ãç´àÅ×Í´
µè
Ó
«Õ´¨Ò¡àÁç´àÅ×ʹᴧᵡ
à¡Ô´¹éÍÂÁÒ¡¡ÇèÒÃéÍÂÅÐ
0.1
ÂÒäÃá¿Á»Ô¹ÁÕ»‾Ô¡ÔÃÔÂÒµèÍÂÒÍ×è¹æÁÒ¡ÁÒÂ
à¹×èͧ
¨Ò¡à»ç¹µÑÇ¡ÃеØ鹡Ò×ӧҹ¢Í§à͹ä«ÁìµèÒ§æ—Õèáç
àªè
¹
¡ÃеØé¹ä«âµâ¤ÃÁ
¾Õ 450 (cytochrome P 450)
Å´ÃдѺÂÒ¤ØÁ¡Óà¹Ô´ã¹¡ÃÐáÊàÅ×Í´
à¾ÔèÁ¡ÒâѺàÁ
—Òâ´¹ (methadone) —ÓãËéà¡Ô´ÍÒ¡Òö͹ÂÒ
áÅÐ
à¾ÔèÁ¡ÒâѺ¡ÅÙ⤤͵ԤÍ´ì (glucocorticoids) —ÓãËé
à¡Ô´µèÍÁËÁǡ䵗ӧҹµèÓä´é´Ñ§¹Ñ鹤ÇÃÃÐÇѧ㹡ÒÃãªé
ÂÒÍ×è¹ÃèÇÁ¡ÑºÂÒäÃá¿Á»Ô
¹
ÂÒãËÁèÍÕ¡µÑÇ˹Öè
§
㹡ÅØèÁäÿÒäÁ«Ô
¹
¤×
Í
äÃ
¿ÒÅÒ«ÔÅ (rifalazil, RLZ) (KRM1648 ËÃ×
Í
benzoxazinorifamycin) à»ç¹ÂÒ¡Öè§Êѧà¤ÃÒÐËì—ÕèÍÍ¡
ė¸ìÔ¹Ò¹
¨Ò¡¡Ò×´Åͧã¹Ë¹Ù27 ¾ºÇèÒÁÕ»ÃÐÊԗ¸ÔÀÒ¾

¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
´Õ¡ÇèÒäÃá¿Á¾Ô«Ô¹áÅÐäÿҺٵÔ
¹
Êèǹ㹤¹¾ºÇèÒÂÒäÃ
¿ÒÅÒ«ÔÅÍÒ¨—ÓãËéà¡Ô´¼Å¢éÒ§à¤Õ§¤ÅéÒÂä¢éËÇÑ´ãˍèÅ´
¨Ó¹Ç¹àÁç´àÅ×Í´¢ÒÇáÅÐà¡Ãç´àÅ×Í´ªÑèǤÃÒÇ
áµè
»ÃÐÊԗ¸ÔÀÒ¾äÁèä´é´Õ¡ÇèÒÂÒäÃá¿Á¾Ô«Ô
¹
´Ñ§¹Ñ鹡ÒÃãªéÂÒ
äÿÒÅÒ«ÔŤ§µéͧÃÍ¡ÒÃÈÖ¡ÉÒÍ×è¹ÁÒʹѺʹعà¾ÔèÁàµÔ
Á
¾ÑÂÃÒ«Ô¹ÒäÁ´ì (pyrazinamide)
¾ÑÂÃÒ«Ô¹ÒäÁ´ì (pyrazinamide) à»ç¹ÂÒÍա˹Öè
§
ª¹Ô´ã¹¡ÅØèÁÂÒËÅѡ㹡ÒÃÃÑ¡ÉÒÇѳâä—Ø¡ÃٻẺ
ú¡Ç¹¡Òâ¹Ê觢ͧàÂ×èÍËØéÁà«ÅÅìáÅТѴ¢ÇÒ§¡ÒÃÊÃéÒ§
¾Åѧ§Ò¹ã¹Êèǹ¢Í§¡Ã´ä¢Áѹ¢¹Ò´ÊÑé¹ (short-chain,
fatty-acid precursors) (ÀÒ¾—Õè 1) ¢¹Ò´ã¹¼Ùéãˍè
20-25 ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ 1 ¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
ÂÒ
ÊÒÁÒö¼èÒ¹à¢éÒÃкº»ÃÐÊҗÊèǹ¡ÅÒ§ä´é
´ÕÃдѺÂÒ
ã¹¹éÓä¢ÊѹËÅѧà—èҡѺ㹡ÃÐáÊàÅ×Í´
¶Ù¡¡Ó¨Ñ´â´ÂµÑ
º
áµè¢ÑºÍÍ¡—Ò§»ÑÊÊÒÇÐ
ÃдѺÂÒÍÒ¨ÊÐÊÁËÒ¡¼Ùé»èÇÂ
äµÇÒÂ
´Ñ§¹Ñ鹤ÇÃÅ´¢¹Ò´ÂÒŧàËÅ×Í 25-35 ÁÔÅÅÔ¡ÃÑ
Á
µè͹éÓ˹ѡµÑÇ 1 ¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
ÊÒÁÇѹµèÍÊÑ»´ÒËìÍÒ¡ÒÃ
¢éÒ§à¤Õ§
ä´éá¡è¼×è
¹
¤Å×è¹äÊéÍÒà¨Õ¹
àº×èÍÍÒËÒÃ
¡Ã´
ÂÙÃÔ¤ã¹àÅ×Í´ÊÙ
§
¡ÒÃà»ç¹¾Ôɵè͵Ñ
º
ÍÂèÒ§äáç´Õà¡Ô´¾Ô
É
µè͵Ѻ¹éÍÂÁÒ¡
ËÒ¡ãªéÂÒ¢¹Ò´¹éÍ¡ÇèÒ 25 ÁÔÅÅÔ¡ÃÑ
Á
µè͹éÓ˹ѡµÑÇ 1 ¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹

¨Ò¡¡ÒÃÈÖ¡ÉÒ
¼Ùé»èÇÂ
430 ÃÒÂ
¢Í§
Yee áÅФ³Ð28 ã¹»Õ¾.È. 2533 ¶Ö
§
2542 ¾ºÇè
Ò
¾ÑÂÃÒ«Ô¹ÒäÁ´ì¡èÍãËéà¡Ô´¼Å¢éÒ§à¤Õ§´éÒ¹
µÑºÍÑ¡àʺáÅм×è¹ÁÒ¡¡ÇèÒÂÒËÅÑ¡µÑÇÍ×è¹æ (¾ÑÂÃÒ«Ô¹Ò
äÁ´ìÃéÍÂÅÐ 6 äÍâ«ä¹ÍÐÊÔ´ÃéÍÂÅÐ 4 äÃá¿Á»Ô¹ÃéÍÂ
ÅÐ 3) â´Â¾ºÁÒ¡ã¹à¾ÈˍÔ
§
ÍÒÂØÁÒ¡¡ÇèÒË¡ÊÔº»Õ
àª×éͪҵÔàÍàªÕ
Â
áÅÐÀÒÇÐÀÙÁÔ¤ØéÁ¡Ñ¹º¡¾Ãèͧ
ÍÒ¡ÒûǴ
µÒÁ¢é;ºä´ééÃéÍÂÅÐ 40 «Ö觵ͺʹͧµèÍ¡ÒÃãËéÂÒµéÒ¹
¡ÒÃÍÑ¡àʺ—ÕèäÁèãªèÊàµÕÂÃÍ´
ìâ´ÂäÁè¨Óà»ç¹µéͧËÂØ´ÂÒ
ÍÕá—ÁºÙ—ÍÅ (ethambutol)
ÍÕá—ÁºÙ—ÍÅ (ethambutol) à»ç¹ÂÒËÅѡ㹡ÒÃ
ÃÑ¡ÉÒÇѳâä—Ø¡ÃٻẺ
ãªéªèÇ»éͧ¡Ñ¹¡Òô×éÍÂÒ
äÃá¿Á»Ô
¹
àÁ×èÍà¡Ô´¡Òô×é͵èÍÂÒäÍâ«ä¹ÍÐÊÔ´áÅé
Ç
µÑé§áµèáá
ÂѺÂÑ駡ÒÃÊÃéÒ§ÍÐÃÒºÔ⹡ÒáŤᵹ¢Í§¼¹Ñ
§
à«ÅÅìÂÒ¼èÒ¹à¢éÒàÂ×èÍËØéÁÊÁͧ—ÕèÁÕ¡ÒÃÍÑ¡àʺä´éáµèäÁèÁÕ¡ÒÃ
ÃÒ§ҹ»ÃÐÊԗ¸Ô¼ÅµèÍ¡ÒÃÃÑ¡ÉÒÇѳâäàÂ×èÍËØéÁÊÁͧ29
¢¹Ò´ÂÒã¹¼Ùéãˍè 15-20 ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ 1
¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
ÂÒ¶Ù¡¢ÑºÍÍ¡—Ò§äµ
´Ñ§¹Ñ鹤ÇÃÅ´¢¹Ò´
ÂÒŧàÁ×èͤèÒ¡ÒáӨѴ¤ÃÕÍеԹÕ
¹
¹éÍ¡ÇèÒ 20 ÁÔÅÅÔÅÔµÃ
µè͹җռŢéÒ§à¤Õ§¢Í§ÂÒÍÕá—ÁºÙ—ÍÅ
ä´éá¡èÅ´
ÃдѺ¡ÒÃÁͧàËç¹áÅÐÊٍàÊÕ¡ÒÃá¡áÂÐÊÕá´§áÅÐÊÕ
à¢ÕÂÇ
¢Ö鹡Ѻ¢¹Ò´ÂҗÕèãªé (¾ºÃéÍÂÅÐ 18 àÁ×èÍãªé¢¹Ò´
ÂÒÁÒ¡¡ÇèÒ 30 ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ 1 ¡ÔâÅ¡ÃÑÁµè
Í
Çѹ) â´ÂÍÒ¨à¡Ô´Ë¹Öè§ËÃ×͗Ñé§ÊͧµÒ¡çä´é¨Ö§äÁè¹ÔÂÁãªé
ã¹à´ç
¡
à¹×èͧ¨Ò¡äÁèÊÒÁÒöà½éÒÃÐÇѧä´é Leibold30 ¾ºÇè
Ò
äÁèÁÕ¤ÇÒÁᵡµèҧ㹡ÒÃà¡Ô´»ÑËÒ¡ÒÃÅ´ÃдѺ¡ÒÃÁͧ
àËç

¹
àÁ×èÍà»ÃÕºà—ÕºÃÐËÇèÒ§¡ÒÃãªéÂÒÍÕá—ÁºÙ—ÍÅ
¢¹Ò´ 15 ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ 1 ¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
¡Ñº¡ÒÃäÁèãªéÂÒÍÕá—ÁºÙ—ÍÅ
ÍÂèÒ§äáçµÒÁ¤ÇõÃǨ
ÃдѺÊÒÂµÒ (Snellen chart) áÅСÒÃá¡áÂÐÊÕ
(Ishihara tests) äÇéà»ç¹¾×é¹°Ò¹¡è͹¡ÒÃÃѺ»ÃЗҹ
ÂÒ
¨Ò¡¹Ñé¹µÃǨÊÒµҗءà´×͹
àÁ×èͼÙé»èÇÂÁÒµÃǨ
µÔ´µÒÁ
áÅÐËÂØ´Âҗѹ—Õ—ÕèÁÕ¤ÇÒÁ¼Ô´»¡µÔ¢Í§ÊÒµÒ

»Õ—Õè 19 ©ºÑº—Õè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
à¾ÃÒÐÍÒ¨ÊٍàÊÕ¡Ò×ӧҹ¢Í§ÊÒµÒẺ¶ÒÇÃä´é
¼Å¢éÒ§à¤Õ§Í×è
¹
àªè
¹
¼×è
¹
»ÅÒ»ÃÐÊҗÍÑ¡àʺ
ä«â¤Å«ÕÃÕ¹ (cycloserine)
ä«â¤Å«ÕÃÕ¹ (cycloserine) à»ç¹ÂÒÍѹ´ÑºÃͧ
㹡ÒÃÃÑ¡ÉÒàª×éÍÇѳâä´×éÍÂÒ
ÍÒ¨ãªéªÑèǤÃÒÇÃèÇÁ¡Ñºã¹
¡Ã³Õ¼Ùé»èÇÂà¡Ô´µÑºÍÑ¡àʺ
ÂѺÂÑ駡ÒÃÊÃéÒ§à»çºµÔâ´ä¡Å
᤹ (peptidoglycan) ¢¹Ò´ÂÒã¹¼Ùéãˍè 10-15
ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ 1 ¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
¢¹Ò´ÊÙ§ÊØ
´
1,000 ÁÔÅÅÔ¡ÃÑÁµèÍÇÑ
¹
â´Â»¡µÔãªé¢¹Ò´ 500-750
ÁÔÅÅÔ¡ÃÑÁµèÍÇÑ
¹
áºè§ãËéÇѹÅÐ 2 ¤ÃÑé
§
äÁè¤ÇÃãªéÂÒã¹
ˍԧµÑ駤ÃÃÀìËÃ×ÍäµÇÒ—ÕèÁÕ¤èÒ¡ÒáӨѴ¤ÃÕÍеԹÕ
¹
¹éÍÂ
¡ÇèÒ 50 ÁÔÅÅÔÅԵõè͹җÕÃÇÁ—Ñé§à¾ÔèÁ¡Òêѡä´éã¹¼Ùé
»èÇ—ÕèÁյѺÍÑ¡àʺ¨Ò¡ÊØÃÒ
¼Å¢éÒ§à¤Õ§—Ò§Ãкº»ÃÐÊҗ
¨Ò¡ÂÒä«â¤«ÕÃÕ¹¾ºä´éµÑé§áµè»Ç´ÈÕÃÉÐ
ÍÒ¡Ò×ҧ¨Ô
µ
¨¹¶Ö§ªÑ
¡
áµè¾º»ÅÒ»ÃÐÊҗÍÑ¡àʺ¹éÍÂÁÒ¡
â´Â
ÃÒ§ҹ¨Ò¡ Murray31 ¾ºÇèÒËÒ¡ÃѺ»ÃЗҹÂÒ 500
ÁÔÅÅÔ¡ÃÑ
Á
ÇѹÅÐ 2 ¤ÃÑé
§
¾ºÍÒ¡Òêѡä´é¶Ö§ 16% áµè
¶éÒÃѺ»ÃЗҹÂÒàËÅ×Í 500 ÁÔÅÅÔ¡ÃÑ
Á
ÇѹÅФÃÑé
§
¾ºÍÒ¡Òêѡà¾Õ§ÃéÍÂÅÐ 3 ÍÒ¨ãËéä¾ÃÔ´Í¡«Ô
¹

(pyridoxine) ÇѹÅÐ 100-200 ÁÔÅÅÔ¡ÃÑÁ»éͧ¡Ñ¹¡ÒÃ
à¡Ô´¼Å¢éÒ§à¤Õ§—Ò§»ÃÐÊҗä´é¤ÇùѴµÃǨµÔ´µÒÁ
ÍÒ¡Ò×ҧ¨ÔµáÅлÃÐÊҗÍÂèÒ§ÊÁèÓàÊÁÍ
ÇÑ´ÃдѺÂÒ
ã¹àÅ×Í´à¾×èÍ»ÃѺ¢¹Ò´ÂÒãËéàËÁÒÐÊÁ
àÍä—â͹ÒäÁ´ì (ethionamide)
àÍä—â͹ÒäÁ´ì (ethionamide) ÂÒÍѹ´ÑºÃͧ
ÊÓËÃѺàª×éÍÇѳâä—Õè´×éÍÂÒÍÕ¡ª¹Ô´Ë¹Öè
§
ÂѺÂÑ駡ÒÃÊÃéÒ§
¡Ã´äÁâ¤ÅÔ¡ (mycolic acid) ¢¹Ò´ÂÒã¹¼Ùéãˍè 1520
ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ 1 ¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
â´Â»¡µÔãªé
¢¹Ò´ 500-750 ÁÔÅÅÔ¡ÃÑÁµèÍÇÑ
¹
áºè§ãËéÇѹÅÐ 1-2
¤ÃÑé
§
â´ÂãËé¡è͹¹Í¹ËÃ×Í¡è͹ÍÒËÒÃÁ×éÍËÅÑ
¡
à¹×èͧ¨Ò¡
¼Å¢éÒ§à¤Õ§Êèǹãˍèà¡ÕèÂǡѺÃкº—Ò§à´Ô¹ÍÒËÒÃ
—ÓãËé
àÊÕ¡ÒÃÃѺÃÙéÃÊ
¤Å×è¹äÊéÍÒà¨Õ¹
àº×èÍÍÒËÒÃ
»Ç´—éͧ
ÍÒ¨¾ºµÑºÍÑ¡àʺä´éÃéÍÂÅÐ 2 à¾ÃÒÐâ¤Ã§ÊÃéÒ§¤ÅéÒÂ
äÍâ«ä¹ÍÐÊÔ
´
´Ñ§¹Ñ鹤ÇÃÃÐÇѧ¡ÒÃãªéÂÒã¹¼Ùé—ÕèÁÕâäµÑ
º
ÍÂÙèà´Ô
Á
áÅÐËÁÑè¹µÔ´µÒÁ¡Ò×ӧҹ¢Í§µÑºÍÂèÒ§ÊÁè
Ó
àÊÁÍ
¼Å¢éÒ§à¤Õ§—Ò§ÃкºµèÍÁäÃé—è
Í
àªè
¹
àµéÒ¹Áâµ
¢Öé
¹
¼ÁÃèǧ
µèÍÁ¸ÑÂÃÍ´ì—Ó§Ò¹µè
Ó
ÊٍàÊÕ¤ÇÒÁµéͧ
¡Ò×ҧà¾È
ÍÒ¨¾º»ÑËÒ¡ÒûÃѺÃдѺ¹éÓµÒÅã¹¼Ùé»èÇÂ
àºÒËÇÒ¹ä´é¹Í¡¨Ò¡¹ÕéÂѧÁÕÃÒ§ҹ¾º»ÅÒ»ÃÐÊҗ
ÍÑ¡àʺ
»ÃÐÊҗµÒÍÑ¡àʺ

ÇÔµ¡¡Ñ§ÇÅ
«ÖÁàÈÃé
Ò
áÅÐ
ÍÒ¡Ò×ҧ¨Ôµä´é»ÃÐÁÒ³ÃéÍÂÅÐ 1-2
äÁè¤ÇÃãªéÂÒ¹Õéã¹ËÔ§µÑ駤ÃÃÀìà¹×èͧ¨Ò¡ÂÒ¼èҹá
ä´éÊèǹ¼Ùé»èÇÂäµÇÒ—ÕèÁÕ¤èÒ¡ÒáӨѴ¤ÃÕÍеԹÕ
¹
¹éÍÂ
¡ÇèÒ 30 ÁÔÅÅÔÅԵõè͹җդÇÃÅ´¢¹Ò´ÂÒàËÅ×Í 250500
ÁÔÅÅÔ¡ÃÑÁµèÍÇÑ
¹

¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
ÊàµÃçºâµäÁ«Ô¹ (streptomycin)
Í͡ė¸ìÔâ´ÂÂѺÂÑ駡ÒÃÊÃéÒ§â»ÃµÕ¹¢Í§àª×é
Í
Çѳâä
¢¹Ò´ÂÒã¹¼Ùéãˍè 15 ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ 1
¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
ÍÒ¨ãËé 10 ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ 1
¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
¶éÒÍÒÂØÁÒ¡¡ÇèÒ 59 »ÕËÃ×ͼÙé»èÇÂäµÇÒÂ
â´ÂÊèǹãˍèãËéÂÒ 5-7 ÇѹµèÍÊÑ»´ÒË
ì㹪èǧ 2-4
à´×͹áá
¨Ò¡¹Ñ鹨֧ŴàËÅ×Í 2-3 ÇѹµèÍÊÑ»´ÒË
ì
¼Å¢éÒ§à¤Õ§—ÕèÊӤэ—ÕèÊØ
´
¤×
Í
¾ÔɵèÍÃкºËٗÑé
§
¡ÒÃä´éÂÔ¹áÅСÒ×çµÑ
Ç
¾º»Ñ¨¨ÑÂàÊÕè§à¾ÔèÁ¢Öé¹ã¹¼ÙéÊÙ
§
ÍÒÂØˍԧµÑ駤ÃÃÀ
ì¼ÙéãªéÂҢѺ»ÑÊÊÒÇÐÃèÇÁ´éÇÂ
¼ÙéãªéÂÒ
streptomycin ¢¹Ò´ÊÙ
§
ËÃ×Í¢¹Ò´ÂÒÊÐÊÁÁÒ¡¡Çè
Ò
100-120 ¡ÃÑ
Á
¼Å¢éÒ§à¤Õ§Í×è
¹
ä´éá¡è¾ÔɵèÍÃкº
»ÃÐÊҗ
¾ºÁÕÍÒ¡ÒêÒÃͺ»Ò¡ä´é—ѹ—ÕËÅѧ©Õ´ÂÒ
¾Ô
É
µèÍÃкºäµâ´Â¾º¹éÍ¡ÇèÒÂÒµÑÇÍ×è¹ (amikacin,
kanamycin, or capreomycin) ÁÕ¡ÒÃÈÖ¡ÉÒã¹»Õ¾.È.
2490 32¾º¼Ùé»èÇÂäµÇÒ—ÕèµéͧËÂØ´ÂÒ»ÃÐÁÒ³ÃéÍÂÅÐ 2
´Ñ§¹Ñ鹤ÇõÃǨ¡Ò×ӧҹ¢Í§äµ
¡ÒÃä´éÂÔ¹àÊÕ§
ÃÇÁ
¶Ö§¡Ò×çµÑÇäÇéà»ç¹¾×é¹°Ò¹¡è͹àÃÔèÁÂÒÊàµÃçºâµäÁ«Ô
¹

ÍÐÁÔ¤Ò«Ô¹áÅФҹÒäÁ«Ô¹ (amikacin and
kanamycin)
ÂÒÍѹ´ÑºÃͧª¹Ô´©Õ´ÍÕ¡ª¹Ô´Ë¹Öè§ã¹¡ÒÃÃÑ¡ÉÒ
Çѳâä´×éÍÂÒ
«Öè§ÂÒÊͧª¹Ô´¹ÕéÊÒÁÒö´×éÍ¢éÒÁ¡Ñ¹ä´éÊèǹ
ÊÒ¾ѹ¸ìؗÕè´×éÍ streptomycin ÂѧµÍºÊ¹Í§µèÍÂÒÊͧ
ª¹Ô´¹Õéä´é¢¹Ò´áÅÐáÅмŢéÒ§à¤Õ§µèÍÃкºËÙàËÁ×͹
ÂÒ streptomycin áµè¡èÍãËéà¡Ô´¼Å¡ÃЗº´éÒ¹¡Ò×ç
µÑǹéÍ¡Çè
Ò
¨Ò¡ÃÒ§ҹ¡ÒÃÈÖ¡ÉҢͧ Black áÅÐ
¤³Ð33 ¾ºÇèÒÂÒ amikacin ¡èÍãËéà¡Ô´¡ÒÃÊٍàÊÕ¡ÒÃ
ä´éÂÔ¹àÊÕ§¤ÇÒÁ¶ÕèÊÙ§ä´é¶Ö§ÃéÍÂÅÐ 24 áÅоºÍѵÃÒ¡ÒÃ
à¡Ô´ÊÙ§¢Öé¹ã¹ÃÒ—Õèä´éÂÒ¢¹Ò´ÊÙ§áÅÐËÃ×ÍÃÐÂÐàÇÅÒ¹Ò¹
¢Öé
¹
ÂÒ amikacin áÅÐ kanamycin —ÓãËéà¡Ô
´
¼ÅàÊÕµèÍäµÁÒ¡¡ÇèÒÂÒ streptomycin â´Â੾ÒÐÍÂèÒ§
ÂÔè§ÃÒ—ÕèÁÕ¤èÒ¤ÃÕÍеԹչÊÙ§ÍÂÙè¡è͹
ãªéÂÒ¢¹Ò´ÊÙ
§
áÅÐ
ä´éÃѺÂÒÍ×蹗ÕèÁÕ¼ÅàÊÕµèÍäµÃèÇÁ´éÇÂ
à¹×èͧ¨Ò¡ÂҢѺÍÍ¡
—Ò§äµ
¨Ö§¤ÇÃãªéÂÒ´éǤÇÒÁÃÐÁÑ´ÃÐÇÑ
§
ÃÇÁ—Ñ駵ÃǨ
¡Ò×ӧҹ¢Í§äµà»ç¹ÃÐÂÐæ
¹Í¡¨Ò¡¹ÕéÂѧÁռŵèÍäµ
¢Í§—Òá㹤ÃÃÀìáÅСèÍãËéà¡Ô´ËÙ¾Ô¡ÒÃáµè¡Óà¹Ô
´
´Ñ
§
¹Ñé¹äÁè¤ÇÃãªéÂÒÊͧª¹Ô´¹Õéã¹ËÔ§µÑ駤ÃÃÀ
ì
¤Ò»ÃÕâÍäÁ«Ô¹ (capreomycin)
¤Ò»ÃÕâÍäÁ«Ô¹ (capreomycin) ÂÒ©Õ´ãªéä´é—Ñé
§
à¢éÒ¡ÅéÒÁà¹×éÍáÅÐà¢éÒËÅÍ´àÅ×Í´´Ó
ãªéÃÑ¡ÉÒÇѳâä´×é
Í
ÂÒ
¢¹Ò´ÂÒã¹¼Ùéãˍè 15 ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ 1
¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
ÊèǹãˍèãËéÂÒ 5-7 ÇѹµèÍÊÑ»´ÒËìã¹
ªèǧáá
áÅÐÅ´àËÅ×Í 2-3 ÇѹµèÍÊÑ»´ÒË
ìã¹ 2-3
à´×͹¶Ñ´ÁÒËÃ×ÍËÅѧ¨Ò¡¼Åà¾ÒÐàª×éÍ¡ÅѺÁÒà»ç¹»¡µÔ
ÍÂèÒ§äáç´Õ¤ÇÃÅ´¢¹Ò´ÂÒã¹¼ÙéÊÙ§ÍÒÂؼÙéÁÕÀÒÇÐ䵗ӧҹ
º¡¾Ãèͧ

ÀÒÇÐâ»áµÊà«ÕÂÁËÃ×ÍáÁ¡¹Õà«ÕÂÁµè
Ó
áÅÐ

»Õ—Õè 19 ©ºÑº—Õè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
äÁè¤ÇÃãªéÂÒã¹ËÔ§µÑ駤ÃÃÀì¹Í¡¨Ò¡¹ÕéÂѧú¡Ç¹¡Ò×ç
µÑ
Ç
—ÓãËéä´éÂÔ¹àÊÕ§¼Ô´»¡µÔã¹ËÙáÅÐËÙ˹ǡä´é¡è͹
¡ÒÃãªéÂÒ¤ÇõÃǨ¡Ò×ӧҹ¢Í§äµ
ÃдѺà¡Å×ÍáÃèâ»
áµÊà«ÕÂÁáÅÐáÁ¡¹Õà«ÕÂÁ
äÇéà»ç¹¾×é¹°Ò¹áÅеÃǨ
ÃÐËÇèÒ§¡ÒÃãªéÂÒà»ç¹ÃÐÂÐæ
´éÇÂ
¾ÒÃÒÍÐÁÔ⹫ÒÅÔÊÔÅÔ
¡
áÍÊÔ
´
(para-aminosalicylic
acid)
¾ÒÃÒÍÐÁÔ⹫ÒÅÔÊÔÅÔ
¡
áÍÊÔ
´
(paraaminosalicylic
acid) ¢Ñ´¢ÇÒ§¡Ãкǹ¡ÒÃàÁµÒâºÅÔ
ÊÁ¢Í§¡Ã´â¿ÅÔ¡áÅÐàËÅç
¡
ª¹Ô´ÃѺ»ÃЗҹ¢¹Ò´ 812
¡ÃÑ
Á
áºè§ãËé 2-3 ¤ÃÑ駵èÍÇÑ
¹
ÁÕ¡ÒÃÃǺÃÇÁ34¼Ùé»èÇÂ
Çѳâä 7,492 ÃÒÂ
¾ºÇèÒ 38 ÃÒ (ÃéÍÂÅÐ 0.5) à¡Ô
´
µÑºÍÑ¡àʺ
¼Å¢éÒ§à¤Õ§Í×è
¹
ä´éá¡è¡Òôٴ«ÖÁä¢Áѹ¼Ô
´
»¡µÔÃдѺâ¿àŵã¹àÅ×Í´µè
Ó
µèÍÁ¸ÑÂÃÍ´ì—Ó§Ò¹µè
Ó
¡ÒÃá¢ç§µÑǢͧàÅ×Í´¼Ô´»¡µÔ´Ñ§¹Ñ鹤ÇõÃǨàÅ×Í´—Ò§
Ëéͧ»‾ԺѵԡÒÃÍÂèÒ§ÊÁèÓàÊÁ͗ء 1-3 à´×͹
¿ÅÙÍÍâäÇÔâ¹âŹ (fluoroquinolones)
¿ÅÙÍÍâäÇÔâ¹âŹ (fluoroquinolones) ä´éá¡è
ÅÕâÇ¿ÅÍ¡«Ò«Ô¹ (levofloxacin) ÁÍ¡ÊÔ¿ÅÍ¡«Ò«Ô
¹

(moxifloxacin, MXF) áÅСҵԿÅÍ¡«Ò«Ô
¹
(gatifloxacin) ¨Ò¡¡Ò×´Åͧã¹Ë¹Ù35 ¾ºÇèÒàÁ×èÍãËé
ÂÒÁÍ¡ÊÔ¿ÅÍ¡«Ò«Ô¹ÃèÇÁ¡ÑºäÃá¿Á¾Ô«Ô¹áÅÐä¾ÃÒ«Ô¹Ò
äÁ´ì (MXF-RIF-PZA) ÁÕ»ÃÐÊԗ¸ÔÀҾ㹡Òæè
Ò
àª×éÍÇѳâä´Õ¡ÇèÒÂÒäÍâ«ä¹ÍÐÊÔ
´
äÃá¿Á¾Ô«Ô¹áÅÐä¾
ÃÒ«Ô¹ÒäÁ´ì (INH-RIF-PZA) ÂÒ㹡ÅØèÁ¹ÕéÍ͡ė¸
ìÔ
ÂѺÂÑ駡ÒÃÊÃéÒ§¡Ã´´ÕÍÍ¡«ÕäÃ⺹ÔǤÅÕÍÔ¤ (DNA) ¶Ö
§
áÁéäÁèä´éÃѺ¡ÒÃÂÍÁÃѺ¨Ò¡Í§¤ì¡ÒÃÍÒËÒÃáÅÐÂÒ
áµè¶Ù
¡
¹ÓÁÒãªéã¹ÃÒ—Õè´×éÍÂÒËÃ×͗¹¼Å¢éÒ§à¤Õ§¢Í§ÂÒËÅÑ¡äÁè
ä´é«Öè§ã¹Í¹Ò¤µÂÒ¡ÅØèÁ¿ÅÙÍÍâäÇÔâ¹âŹ¹ÕéÍÒ¨¶Ù¡¹ÓÁÒ
ãªéà»ç¹ÂÒËÅѡ㹡ÒÃÃÑ¡ÉÒÇѳâä—Ñ駴×éÍÂÒáÅÐäÁè´×éÍÂÒ
ä´é¢¹Ò´¢Í§ÂÒÅÕâÇ¿ÅÍ¡«Ò«Ô¹ 500-1,000 ÁÔÅÅÔ¡ÃÑ
Á
µèÍÇÑ
¹
¢¹Ò´¢Í§ÂÒÁÍ¡ÊÔ¿ÅÍ¡«Ò«Ô¹ 400 ÁÔÅÅÔ¡ÃÑ
Á
µèÍÇÑ
¹
ÂÒ¡ÅØèÁ¹Õé¼èÒ¹à¢éÒÃкº»ÃÐÊҗÊèǹ¡ÅÒ§äÁè´Õ¹Ñ
¡
»ÃÐÁÒ³ÃéÍÂÅÐ 16-20 ¢Í§ÃдѺÂÒ㹡ÃÐáÊàÅ×Í´
ÃÇÁ—Ñé§Âѧ´×éÍÂÒä´éÃÇ´àÃç
Ç
¨Ö§¤ÇÃàÅ×Í¡ãªéÂÒãËéàËÁÒÐ
ÊÁ
¼Å¢éÒ§à¤Õ§Ãкº—Ò§à´Ô¹ÍÒËÒà (ÃéÍÂÅÐ 0.51.8)
ä´éá¡è¤Å×è¹äÊé—éͧÍ×
´
Ãкº»ÃÐÊҗ (ÃéÍÂÅÐ
0.5) ä´éá¡èàÇÕ¹ÈÕÃÉÐ
»Ç´ÈÕÃÉÐ
¹Í¹äÁèËÅÑ
º
Ãкº
¼ÔÇ˹ѧ (ÃéÍÂÅÐ 0.2-0.4) ä´éá¡è¼×è
¹
¤Ñ
¹
¼×è¹á¾éáʧ
ÂÒÅ´¡Ã´áÅÐÂҗÕè
ÁÕ
Êèǹ»ÃСͺ¢Í§
»ÃШغǡú¡Ç¹¡Òôٴ«ÖÁÂÒ¡ÅØèÁ¿ÅÙÍÍâäÇÔâ¹âŹ
¤ÇÃÃѺ»ÃЗҹÂÒËèÒ§¨Ò¡ÂÒàËÅèÒ¹ÕéÍÂèÒ§¹éÍÂÊͧªÑèÇâÁ§
ÂÒ¡ÅØèÁ¹Õé¶Ù¡¢ÑºÍÍ¡—ҧ䵻ÃÐÁÒ³ÃéÍÂÅÐ 80 ¨Ö§¤ÇÃ
»ÃѺ¢¹Ò´ÂÒàÁ×èͼÙé»èÇÂÁÕ¤èÒ¡ÒáӨѴ¤ÃÕÍеԹÕ
¹
¹éÍ¡Çè
Ò

50 ÁÔÅÅÔÅԵõè͹җչ͡¨Ò¡¹ÕéÂÒäÁè¶Ù¡¡Ó¨Ñ´â´Â¡ÒÃ
¿Í¡äµ´Ñ§¹Ñé¹äÁèµéͧà¾ÔèÁ¢¹Ò´ÂÒÍÕ¡ËÅѧÅéÒ§äµ
ÂÒ¡ÅØèÁÍÍ¡«Òâ«ÅÔ´Ôâ¹¹ (oxazolidinones)
ÂÒ»‾ÔªÕǹСÅØèÁãËÁèä´éÃѺ¡ÒÃÂÍÁÃѺâ´Â
ͧ¤ì¡ÒÃÍÒËÒÃáÅÐÂҢͧÊËÃÑ°ÍàÁÃÔ¡Ò
㹡ÒÃÃÑ¡ÉÒ
Ấ—ÕàÃÕÂá¡ÃÁºÇ¡´×éÍÂÒ
Í͡ė¸ìÔâ´ÂÂѺÂÑ駢Ñ鹵͹

¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
áá¢Í§¡ÒÃÊÃéÒ§â»ÃµÕ¹â´Â¡ÒèѺÊèǹ¢Í§äÃâºâ«Á
ª¹Ô´ 50S (ribosomel 50S subunits) —ÕèÊèǹãˍèÍÂÙè
ÀÒÂã¹â´àÁ¹ 5 ¢Í§äÃ⺹ÔǤÅÕÍÔ¤ª¹Ô´ 23S (domain
V of the 23S rRNA) ¹Í¡¨Ò¡¹ÕéÂѧÁÕė¸ìÔµéÒ¹àª×é
Í
Çѳâäã¹Ë¹ÙÍÂèÒ§äáç´ÕÂѧäÁèÁÕÃÒ§ҹ¡ÒÃãªéÂÒ¹Õé㹤¹
ÂÒ¡ÅØèÁÍÐâ«Å (azole drugs)
Miconazole
¡ÅØèÁÂÒÃÑ¡ÉÒàª×éÍÃҗÕèÊÒÁÒöÂѺÂÑ駡ÒÃàµÔºâµ
¢Í§àª×éÍÇѳâää´éàªè
¹
ÂÒäÁ⤹Òâ«Å (miconazole)
ÂÒâ¤ÅäµÃÁÒâ«Å (clotrimizole) ÂÒÍ͡ė¸ìԗÕèÊèǹ
¢Í§â¤ÃâÁâ«Á¢Í§àª×éÍÇѳâä
—ÕèÁÕÊèǹ»ÃСͺ—Ò§à¤ÁÕ
¤ÅéÒÂä«âµâ¤ÃÁ¾Õ 450 (cytochrome P 450
homologs) —Ñé§ã¹ÃÐÂСÓÅѧáºè§µÑÇáÅÐÃÐÂÐÍÂÙè¹Ôè
§
¹Óä»ÊÙè¡ÒÃÈÖ¡ÉÒ¤ÇÒÁÊÑÁ¾Ñ¹¸ìÃÐËÇèÒ§ä«âµâ¤ÃÁ¾Õ 450
áÅФÇÒÁäǢͧàª×é͵èÍÂÒÍÐâ«Å
«Ö觤§µéͧÃÍ¡ÒÃ
ÈÖ¡ÉÒãËÁèæµèÍä»ã¹Í¹Ò¤µ
ËÅÑ¡¡ÒÃÃÑ¡ÉÒÇѳâä
¨Ø´»ÃÐʧ¤ìËÅѡ㹡ÒÃÃÑ¡ÉÒÇѳâä
¤×
Í
¡Ó¨Ñ
´
àª×éÍÇѳâäÍÂèÒ§ÃÇ´àÃç
Ç
Å´¡ÒÃà¡Ô´¡Òô×éÍÂÒ
áÅÐ
»éͧ¡Ñ¹¡ÒáÅѺà»ç¹«éӢͧâäà¾×èÍãËéºÃÃÅØÇѵ¶Ø»ÃÐʧ¤
ì
¨Ö§ÁÕ¡ÒÃãªéÂÒËÅÒª¹Ô´à»ç¹ÃÐÂÐàÇÅÒ¹Ò¹
ËÅÒ—ÄÉ®Õ
¡ÅèÒǶ֧¡ÒáÅÒ¾ѹ¸ìآͧàª×éÍ (mutation) —Õè—ÓãËé
à¡Ô´¡Òô×éÍÂÒ
¾ºÇèÒÁÕ¡ÒáÅÒ¾ѹ¸ìصÒÁ¸ÃÃÁªÒµÔ¢Í§
àª×éÍÇѳâäµèÍÂÒ isoniazid áÅÐ streptomycin
»ÃÐÁÒ³ 1 ã¹ 106 µèÍÂÒäÃá¿Á»Ô¹»ÃÐÁÒ³ 1 ã¹ 108
áÅеèÍÂÒÍÕá—ÁºÙ—ÍÅ»ÃÐÁÒ³ 1 ã¹ 105 ´Ñ§¹Ñé¹ÊÓËÃÑ
º
¡ÒáÅÒ¾ѹ¸ìصèÍÂÒäÍâ«ä¹ÍÐÊÔ´áÅÐäÃá¿Á»Ô¹¾ºã¹
ÍѵÃÒ 1 ã¹ 1014 ¨Ö§à»ç¹¡ÒÃÂÒ¡—Õè¨Ð´×éÍÂÒ 2 ª¹Ô´¹Õé
¾ÃéÍÁ¡Ñ
¹
´Ñ§¹Ñé¹ËÅÒ¡ÒÃÈÖ¡ÉÒáÊ´§ãËéàËç¹ÇèÒ¡ÒÃãËé

ÂÒËÅÒª¹Ô´ÃèÇÁ¡Ñ
¹
»éͧ¡Ñ¹¡ÒÃà¡Ô´àª×éÍ´×éÍÂÒä´éÁÒ¡¡Çè
Ò
¡ÒÃãËéÂÒà¾Õ§ª¹Ô´à´ÕÂÇ
¡ÒÃÃÑ¡ÉÒ㹻Ѩ¨ØºÑ¹¨Ö§á¹Ð¹ÓãËé
ãªéÂÒäÍâ«ä¹ÍÐÊÔ´áÅÐäÃá¿Á»Ô¹ÃèÇÁ¡ÑºÂÒÍ×è
¹
àªè
¹
ÂÒ
ÍÕá—ÁºÙ—ÍÅáÅÐÊàµÃçºâµäÁ«Ô
¹
¼Ùé»èÇÂÊèǹãˍèµÍºÊ¹Í§µèÍ¡ÒÃÃÑ¡ÉÒà»ç¹ÍÂèÒ§
´Õ¾ºÇèÒÁÒ¡¡ÇèÒÃéÍÂÅÐ 80 µÃǨàÊÁËÐäÁ辺àª×é
Í
ÀÒÂ
ËÅѧ¡ÒÃÃѺ»ÃЗҹÂÒ»ÃÐÁÒ³Êͧà´×͹
Êèǹ¼Ùé»èÇ—Õè
àËÅ×ÍÁÕ¡ÒáÅѺà»ç¹«éӢͧâäáÅÐäÁèµÍºÊ¹Í§µèÍ¡ÒÃ
ÃÑ¡ÉÒâ´Â੾ÒÐÍÂèÒ§ÂÔè§ÃÒ—ÕèÃѺ»ÃЗҹÂÒäÁè¹Ò¹¾Í
¼Ùé—ÕèʧÊÑÂÇèÒà»ç¹Çѳâä
¤ÇÃä´éÃѺ¡ÒÃãªéÇÔ
¸Õ
Áҵðҹ㹡ÒÃà¡ç
º
¡ÒùÓÊè
§
¡ÒÃà¾ÒÐàª×éÍáÅÐÂ×¹ÂÑ
¹
¼Å¡ÒÃà¾ÒÐàª×éͨҡÊÔè§Ê觵ÃǨ
ÃÇÁ¶Ö§µÃǨ¤ÇÒÁäÇ
¢Í§àª×éÍÇѳâäµèÍÂÒ»‾ÔªÕǹÐ
â´Âà¡çºàÊÁËÐÊ觵ÃǨ
ÍÂèÒ§¹éÍÂÊÒÁ¤ÃÑé
§
ËèÒ§¡Ñ¹ 8-24 ªÑèÇâÁ§
¶éÒäÁèÊÒÁÒö
à¡çºàÊÁËÐä´éãËé¡ÃеØé¹ãËéäÍ´éǹéÓà¡Å×Íà¢éÁ¢é¹ËÃ×
Í
Êèͧ¡ÅéͧËÅÍ´ÅÁ
áÅÐ᡼Ùé—ÕèʧÊÑÂËÃ×ÍÂ×¹ÂѹÇèÒà»ç
¹
Çѳâä
à¾×èÍÅ´¡ÒÃá¾Ãè¡ÃШÒÂàª×é
Í
̂禅
§
ÃÒ§ҹ¼Ùé
—ÕèµÔ´àª×é͵èÍ˹èǧҹÊØ¢ÀÒ¾ã¹áµèÅо×鹗Õèà¾×èÍ¡ÒÃ
ÃÑ¡ÉÒÍÂèÒ§µèÍà¹×èͧËÅѧ¼Ùé»èÇÂÍÍ¡¨Ò¡âç¾ÂÒºÒÅ
—Ñé
§
ÂѧÊÒÁÒöËÒ¼ÙéµÔ´àª×éÍÃÒÂÍ×蹗ÕèÊÑÁ¼ÑʡѺ¼Ùé»èÇ (µÒÃÒ§
—Õè 3)

¡Ã³Õ—Õè¼ÅàÊÁÕÂÃìËÃ×ͼÅà¾ÒÐàª×éÍà»ç¹»¡µÔËÃ×
Í
ÃÒ—ÕèµÔ´àª×éÍäÇÃÑÊàͪäÍÇÕµÔ´ÂÒàʾµÔ´ª¹Ô´©Õ´à¢é
Ò
ËÅÍ´àÅ×Í´´Ó
ÊÑÁ¼ÑÊã¡ÅéªÔ´¼Ùé»èÇÂÇѳâä
ÍÒ¨ãªéÇÔ
¸Õ
—´Êͺ—Ò§¼ÔÇ˹ѧâ´Â¹Óâ»ÃµÕ¹ÁÒÊ¡Ñ´ãËéºÃÔÊؗ¸ìÔàÃÕ¡
¡Ò×´Êͺ—ÙàºÍÃì¤ÙÅÔ¹ (PPD-tuberculin skin test)
â´Â¡ÒÃãªéÇÔ¸Õ Mantoux ÁÒªèÇÂ㹡ÒûÃСͺ¡ÒÃ
ÇÔ¹Ô¨©Ñ
Â
«Öè§ÇÔ¸Õ¹Õé—Ó§èÒÂ
¼Å¢éÒ§à¤Õ§¹éÍÂ
ÍèÒ¹¼ÅËÅÑ
§
¡Ò×´Êͺ—Õè 48-72 ªÑèÇâÁ§
â´Â¶×ÍÇèÒà»ç¹ºÇ¡
ã¹
¡Ã³Õ´Ñ§µèÍ仹Õé
-¢¹Ò´ÁÒ¡¡ÇèÒËÃ×Íà—èҡѺ 5 ÁÔÅÅÔàÁµÃ
ã¹
ÃÒ—ÕèÊÑÁ¼ÑÊã¡ÅéªÔ´¼Ùé»èÇÂÇѳâä
µÔ´àª×éÍäÇÃÑÊàͪäÍÇÕ
ÀÒÇÐÀÙÁÔ¤ØéÁ¡Ñ¹µè
Ó
ËÃ×ÍÀÒ¾ÃѧÊÕÇԗÂҢͧ»Í´ºè§ÇèÒà¤Â
µÔ´àª×éÍÇѳâäÁÒ¡è͹

»Õ—Õè 19 ©ºÑº—Õè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
-¢¹Ò´ÁÒ¡¡ÇèÒËÃ×Íà—èҡѺ 10 ÁÔÅÅÔàÁµÃ
ã¹
ÃÒ—Õèà´Ô¹—Ò§ÁÒ¨Ò¡áËÅ觗ÕèÁÕ¤ÇÒÁªØ¡¢Í§Çѳâä
µÔ
´
ÂÒàʾµÔ´ª¹Ô´©Õ´à¢éÒËÅÍ´àÅ×Í´´Ó
ËÃ×Íã¹à´ç¡ÍÒÂعéÍÂ
¡ÇèÒ 4 »Õ
-¢¹Ò´ÁÒ¡¡ÇèÒËÃ×Íà—èҡѺ 15 ÁÔÅÅÔàÁµÃ
ã¹
ÃÒ—ÕèäÁèà¤ÂÊÑÁ¼ÑÊáÅÐäÁèÁջѨ¨ÑÂàÊÕ觵èÍ¡ÒÃà¡Ô´âä
¼Ùé—ÕèµÔ´àª×éÍÇѳâä¤ÇÃä´éÃѺ¡ÒõÃǨËÒàª×éÍäÇÃÑ
Ê
àͪäÍÇÕÀÒÂã¹ 2 à´×͹
ËÅѧ¡ÒÃÇÔ¹Ô¨©ÑÂÇèÒà»ç¹Çѳâä
à¾×èÍ»ÃÐ⪹ì㹡ÒÃá¹Ð¹Ó¼Ùé»èÇÂ
¡ÒÃËÒâäµÔ´àª×éÍ©ÇÂ
âÍ¡ÒÊÍ×è¹æ
áÅÐàÅ×Í¡ÂÒµéÒ¹äÇÃÑÊàÍ´Ê
ìâ´ÂÊÒÁÒö
ÃÑ¡ÉÒ´éÇÂÊÙµÃÂÒÁҵðҹä´éÁÕà¾Õ§ºÒ§ÃÒÂà—èÒ¹Ñ鹗ÕèÍÒ¨
µéͧÃÑ¡ÉÒ´éÇÂÃÐÂÐàÇÅҗÕè¹Ò¹¢Öé
¹
ÃÒ§ҹ¨Ò¡ÊËÃÑ
°
ÍàÁÃÔ¡Òã¹»Õ¾.È. 2536-2537 ¾ºÇèÒÃéÍÂÅÐ 14 ¢Í§¼Ùé
»èÇÂÇѳâäµÃǨ¾ºàª×éÍàͪäÍÇÕáÅкҧ¾×鹗Õè
¾ºâäàÍ´ÊìÃèÇÁ¡ÑºÇѳâä¶Ö§ÃéÍÂÅÐ 58
µÒÃÒ§—Õè 3. áÊ´§¤Óá¹Ð¹ÓÊÓËÃѺ¡ÒôÙáÅÃÑ¡ÉÒÇѳâä㹻ÃÐà—ÈÊËÃÑ°ÍàÁÃÔ¡Ò
INH : isoniazid, RIF : rifampicin, PZA : pyrazinamide, EMB : ethambutol, SM : st
reptomycin, TB :
tuberculosis, CDC : Center for Diseases Control and Prevention
-Obtain bacteriologic confirmation and susceptibility testing for patients with
TB or
suspected of having TB
-Place persons with suspected or confirmed smear-positive pulmonary or laryngeal
TB in
respiratory isolation until noninfectious
-Begin treatment of patients with confirmed or suspected TB disease with 1 of th
e
following drug combinations, depending on local resistance patterns: INH, RIF, P
ZA, or
INH, RIF, PZA, EMB, or INH, RIF, PZA, SM
-Report each case of TB promptly to the local public health department
-Perform HIV testing for all patients with TB

-Treat patients with TB caused by a susceptible organism for 6 months, using an
ATS/
CDC-approved regimen
-Reevaluate patients with TB who are smear positive at 3 months for possible non
adherence
or infection with drug-resistant bacilli
-Add >2 new antituberculosis agents when TB treatment failure is suspected
-Perform tuberculin skin testing on all patients with a history of >1 of the fol
lowing: HIV
infection, injection drug use, homelessness, incarceration, or contact with a pe
rson with
pulmonary TB
-Administer treatment for latent TB infection to all persons with latent TB infe
ction, unless
it can be documented that they received such treatment previously

¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
¡ÒõѴÊÔ¹ã¨àÃÔèÁÂÒÃÑ¡ÉÒÇѳâä¤ÇÃãªé¢éÍÁÙÅ´éÒ¹
ÃкҴÇԗÂÒ
ÍÒ¡Ò×ҧ¤ÅÔ¹Ô
¡
¼Å¡ÒõÃǨàÊÁËÐÍÂèÒ§
¹éÍÂÊÒÁ¤ÃÑé
§
áÅÐÀÒ¾—Ò§ÃѧÊÕÇԗÂÒà»ç¹¾×é¹°Ò¹
ÍÂèÒ§
äáç´Õ¤ÇÃàÃÔèÁ¡ÒÃÃÑ¡ÉÒ´éÇÂÂÒÊÕ誹Ô
´
â´ÂäÁèµéͧÃÍ
¼Å¡ÒÃà¾ÒÐàª×éÍÇѳâäáÅСó՗Õè¼ÅàÊÁÕÂÃìà»ç¹»¡µÔáµè
ÍÒ¡Ò×ҧ¤ÅÔ¹Ô¡à¢éÒä´é¡ÑºÇѳâä¡çµÒÁ
¡àÇ鹡óÕÍÂÙè
㹶Ô蹗Õè´×é͵èÍÂÒäÍâ«ä¹ÍÐÊÔ
´
¹éÍ¡ÇèÒÃéÍÂÅÐ 4
ÊÒÁÒöãªéÂÒ 3 ª¹Ô´ä´é
ÂҗÕè¶×ÍÇèÒà»ç¹Áҵðҹ㹡ÒÃÃÑ¡ÉÒà»ç¹Íѹ´Ñ
º
áá
¤×
Í
ÂÒäÍâ«ä¹ÍÐÊÔ
´
ÂÒäÃá¿Á»Ô
¹
ÂÒä¾ÃÒ«Ô
¹ÒäÁ´
ìáÅÐÂÒÍÕá—ÁºÙ—ÍÅ
¨Ö§ÁÕ¡ÒÃáºè§ÃÐÂÐàÇÅÒ¡ÒÃ
ÃÑ¡ÉÒà»ç¹ 2 ªèǧ
¤×
Í
ÃÐÂÐà¢éÁ¢é¹ 2 à´×͹áá
(intensive phase) ãªéÂÒ 4 ª¹Ô´¢éÒ§µé
¹
áÅÐ 4 à´×͹
¶Ñ´ÁÒà»ç¹ÃÐÂеèÍà¹×èͧ (continuation or
maintenance phase) ãªéÂÒ 2 ª¹Ô
´
¤×
Í
ÂÒäÍâ«ä¹
ÍÐÊÔ
´
áÅÐäÃá¿Á»Ô
¹
¡ÒÃÃѺ»ÃЗҹÂÒà»ç¹àÇÅÒ 6 à´×͹ (26
ÊÑ»´ÒËì) à»ç¹Áҵðҹ—Õèãªé¡Ñ¹ã¹»Ñ¨¨ØºÑ
¹

—Ñé§ã¹à´ç¡áÅÐ
¼Ùéãˍè—Õè¼Åà¾ÒÐàª×éÍÇѳâäà»ç¹ºÇ¡
ÊÓËÃѺ㹼Ùéãˍèáºè
§
à»ç¹ËÅÒÂÊٵà (µÒÃÒ§—Õè 4-5) »ÃСͺ´éÇ INH,
RIF, PZA, áÅÐ EMB ÇѹÅФÃÑé§ã¹ 2 à´×͹áá
(Êٵ×Õè 1) ËÃ×ÍÇѹÅФÃÑé§ã¹ 2 ÊÑ»´ÒËìáá
µÒÁ´éÇÂ
2 ¤ÃÑ駵èÍÊÑ»´ÒË
ìã¹ 6 ÊÑ»´ÒËìµèÍÁÒ (Êٵ×Õè 2) ËÃ×
Í
3 ¤ÃÑ駵èÍÊÑ»´ÒËì (Êٵ×Õè 3) ÊÙµÃÂÒàËÅèÒ¹Õéä´éÃѺ¡ÒÃ
ʹѺʹعâ´Â¡ÒÃÈÖ¡ÉÒẺÂé͹ËÅѧ¨Ò¡ The British
Medical Research Council (BMRC) ¾º¡Òô×é
Í
ÂÒäÍâ«ä¹ÍÐÊÔ´áµèäÁè¤è;º¡ÒÃÃÑ¡ÉÒÅéÁàËÅÇËÃ×
Í
¡ÒáÅѺà»ç¹«é
Ó
¶éÒãªéÂÒÃèÇÁ¡Ñ¹—Ñé§ 4 ª¹Ô´ã¹ÃÐÂÐ
à¢éÁ¢é
¹
¶éÒÊÒÁÒöµÃǨÂ×¹ÂѹÇèÒàª×éÍäǵèÍÂÒäÍâ«ä¹
ÍÐÊÔ´áÅÐäÃá¿Á¾Ô«Ô¹¨ÃÔ
§
ÍÒ¨äÁè¨Óà»ç¹µéͧãªéÂÒÍÕ
á—ÁºÙ—ÍÅËÃ×ÍÊÒÁÒöËÂØ´ÂÒä´é—ѹ—ÕËÅѧ—ÃÒº¼Å¡ÒÃ
—´Êͺ
ÍÂèÒ§äáç´Õ¤ÇÒÁà»ç¹¨ÃÔ§ÁÑ¡äÁè—ÃÒº¼Å¡ÒÃ
—´Êͺ¡è͹ 4-8 ÊÑ»´ÒË
ì

»Õ—Õè 19 ©ºÑº—Õè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
µÒÃÒ§—Õè 4. ÊÙµÃÂÒÃÑ¡ÉÒÇѳâä»Í´—Õè¼Åà¾ÒÐàª×éÍà»ç¹ºÇ¡
1 : isoniazid, R : rifampicin, 2 : pyrazinamide, E : ethambutol, wk : week
Initial phase Continuation phase
Regimen Drugs Interval and dose Drugs Interval and dose
1 IRZE 7 days/wk for 56 doses
(8 weeks) or5 days/wk for40 doses
(8 weeks)
IR
IR
7 days/wk for 126 doses
(18 weeks) or
5 days/wk for 90 doses
(18 weeks)
Twice weekly for 36 doses
(18 weeks)
2 IRZE 7 days/wk for 14 doses
(2 weeks) then
twice weekly for 12 doses
(6 weeks) or
5 days/wk for 10 doses
(2 weeks) then
twice weekly for 12 doses
(6weeks)
IR Twice weekly for 36 doses
(18 weeks)
3 IRZE 3 times/wk for 24 doses
(8 weeks)
IR 3 times/wk for 54 doses
(18 weeks)
4 IRE 7 days/wk for 56 doses
(8 weeks) or
5 days/wk for 40 doses
(8 weeks)
IR
IR
7 days/wk for 217 doses
(31 weeks) or
5 days per week for 155 doses
(31 weeks)
Twice weekly for 62 doses
(31 weeks)

¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
µÒÃÒ§—Õè 5. áÊ´§¢¹Ò´ÂҗÕèãªéã¹¼Ùéãˍè
ÃÐÂеèÍà¹×èͧ (continuation or maintenance
phase) ãªéÂÒ 2 ª¹Ô
´
¤×
Í
ÂÒäÍâ«ä¹ÍÐÊÔ
´
áÅÐäÃ
á¿Á»Ô
¹
à»ç¹àÇÅÒÍÂèÒ§¹éÍ 4 à´×͹ (18 ÊÑ»´ÒËì)
â´ÂÊÒÁÒöãËéÂÒä´é—Ñé§ÇѹÅÐ 1 ¤ÃÑé
§
ÊÑ»´ÒËìÅÐ 2 ¤ÃÑé
§
ËÃ×Í 3 ¤ÃÑ駵èÍÊÑ»´ÒË
ì
¹Í¡¨Ò¡¹ÕéºÒ§ÃÒÂÍÒ¨µéͧãËé¡ÒÃÃÑ¡ÉÒÃÇÁ 9
à´×͹
â´Âà¾ÔèÁÃÐÂеèÍà¹×èͧÍÕ¡ 3 à´×͹
´Ñ§µèÍ仹Õé
-â¾Ã§Çѳâä»Í´ (cavity) —ÕèÂѧÁÕ¼Åà¾ÒÐ
àª×éͨҡàÊÁËÐà»ç¹ºÇ¡
ËÅѧÃÑ¡ÉÒ¹Ò¹ 2 à´×͹
-ÃÒ—ÕèäÁèä´éÃѺ»ÃЗҹÂÒä¾ÃÒ«Ô¹ÒäÁ´
ìã¹
ÃÐÂÐà¢éÁ¢é
¹
-ÃÒ—ÕèÃѺ»ÃЗҹÂÒäÍâ«ä¹ÍÐÊÔ´áÅÐäÃ
á¿Á»Ô
¹
ÊÑ»´ÒËìÅФÃÑé
§
áÅÐÂѧÁÕ¼ÅàÊÁËÐà»ç¹ºÇ¡
ÂÒ
¢¹Ò´µèÍÇÑ
¹
¢¹Ò´ 2 ¤ÃÑ駵èÍÊÑ»´ÒË
좹Ҵ 3 ¤ÃÑ駵èÍÊÑ»´ÒË
ì
Isoniazid 5 Á¡./¡¡. ÊÙ§ÊØ´ 300 Á¡. 15 Á¡./¡¡. ÊÙ§ÊØ´ 900 Á¡. 15 Á¡./¡¡. ÊÙ§ÊØ´ 900 Á¡.
Rifampin
Pyrazinamide
10 Á¡./¡¡. ÊÙ§ÊØ´ 600 Á¡.
15-30 Á¡./¡¡. ÊÙ§ÊØ´ 2 ¡.

10 Á¡./¡¡. ÊÙ§ÊØ´ 600 Á¡.
50-70 Á¡./¡¡. ÊÙ§ÊØ´ 4 ¡.
10 Á¡./¡¡. ÊÙ§ÊØ´ 600 Á¡.
50-70 Á¡./¡¡. ÊÙ§ÊØ´ 3 ¡.
Ethambutol 15-25 Á¡./¡¡. 50 Á¡./¡¡. 25-30 Á¡./¡¡.
Streptomycin 15 Á¡./¡¡. ÊÙ§ÊØ´ 1 ¡. 25-30 Á¡./¡¡. ÊÙ§ÊØ´ 1.5 ¡. 25-30 Á¡./¡¡. ÊÙ§ÊØ´ 1.5 ¡.
àÁ×èÍÊÔé¹ÊØ´¡ÒÃÃÑ¡ÉÒ
¡ÒÃÃѺ»ÃЗҹÂÒÃÑ¡ÉÒÇѳâä
¤ÇÃÃѺ»ÃЗҹ
àÇÅÒà´ÕÂÇ¡Ñ
¹
ÍÒ¨ãªéà»ç¹ÂÒª¹Ô´àÁç´ÃÇÁ
à¾×èͧèÒÂáÅÐ
ÊдǡÊÓËÃѺ¼Ùé»èÇÂ
Å´¤ÇÒÁ¼Ô´¾ÅҴ㹡ÒÃÃÑ
º
»ÃЗҹ
ÃÇÁ—Ñé§Å´¡ÒÃà¡Ô´¡Òô×éÍÂÒã¹Í¹Ò¤µ
ÍÂèÒ§
äáç
´ÕÍÒ¨à¾ÔèÁÂÒª¹Ô´àÁç´á¡ºÒ§µÑ
Ç
ã¹ÃÒ—Õè¹éÓ˹Ñ
¡
µÑÇÁÒ¡¡ÇèÒ 90 ¡ÔâÅ¡ÃÑ
Á
à¾ÃÒТ¹Ò´ÂÒáµèÅеÑÇã¹ÂÒ
ª¹Ô´àÁç´ÃÇÁÍÒ¨äÁèà¾Õ§¾Í
àªè
¹
ÂÒä¾ÃÒ«Ô¹ÒäÁ´
ìà»ç
¹
µé
¹
ÃÐÂÐàÇÅÒÃÑ¡ÉÒÃÇÁ 6 à´×͹
â´ÂÁÕÂÒäÍâ«ä¹ÍÐ
ÊÔ´áÅÐäÃá¿Á»Ô
¹
µÅÍ´ÃÐÂÐàÇÅÒ¡ÒÃÃÑ¡ÉÒ
¶éÒµÔ
´
àª×éÍÇѳâäàÂ×èÍËØéÁÊÁͧ
¡Ãд١áÅТé
Í
ÍÒ¨ãËé¡ÒÃÃÑ¡ÉÒ
¹Ò¹¶Ö§ 12 à´×͹ (µÒÃÒ§—Õè 6)

»Õ—Õè 19 ©ºÑº—Õè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
µÒÃÒ§—Õè 6. áÊ´§ÃÐÂÐàÇÅÒ¡ÒÃÃÑ¡ÉÒÇѳâä¹Í¡»Í´
µÓá˹è
§
-µèÍÁ¹éÓàËÅ×ͧ
-¡Ãд١áÅТéÍ
-àÂ×èÍËØéÁ»Í´
-àÂ×èÍËØéÁËÑÇã¨*
-Ãкº»ÃÐÊҗÊèǹ¡ÅÒ§áÅÐàÂ×èÍËØéÁÊÁͧ*
-Çѳâä¡ÃШÒÂ
-Ãкº—Ò§à´Ô¹»ÑÊÊÒÇÐ
-àÂ×èÍËØéÁªèͧ—éͧ
* á¹Ð¹ÓãËéãªéÂҤ͵Ôâ¤ÊàµÕÂÃÍ´ìÃèÇÁ´éÇÂ
¼Ùé»èÇ—ÕèÁÕâä—Ò§ÍÒÂØáÃÃÁÍ×è
¹
¤ÇÃÃÐÇѧ㹡ÒÃ
ãªéÂÒÃÑ¡ÉÒÇѳâä
à¹×èͧ¨Ò¡ÂÒÁÕ»‾Ô¡ÃÔÂҡѺÂÒÍ×è¹æÁÒ¡
ÍÒ¨—ÓãËéÃдѺÂÒ㹡ÃÐáÊàÅ×Í´à»ÅÕè¹á»Å§
¡ÒÃÃÑ¡ÉÒ
äÁèä´é¼Åà—èҗÕè¤ÇÃ
»ÃÐàÁÔ¹¡ÒõͺʹͧµèÍ¡ÒÃÃÑ¡ÉÒâ´ÂÊѧࡵ
¨Ò¡ÍÒ¡ÒÃáÅмšÒõÃǨàÊÁËÐ
¶éÒ¡è͹¡ÒÃÃÑ¡ÉÒÁÕ
¼ÅàÊÁËÐà»ç¹ºÇ¡
á¹Ð¹ÓãËéµÃǨàÊÁËÐËÅѧ¨Ò¡ÃÑ¡ÉÒ
¹Ò¹Êͧà´×͹
â´ÂäÁèµéͧµÃǨÀÒ¾ÃѧÊÕÇԗÂҗÕèÊͧ
à´×͹
ãËéµÃǨËÅѧàÊÃç¨ÊÔ鹡ÒÃÃÑ¡ÉҗÕèË¡à´×͹ä´éàÅÂ
áµèËÒ¡¡è͹¡ÒÃÃÑ¡ÉÒÁÕ¼ÅàÊÁËÐà»ç¹Åº
ãËéµÃǨÀÒ¾
ÃѧÊÕÇԗÂÒËÅѧÃÑ¡ÉÒÊͧà´×͹ᗹ
àÁ×èÍÃÑ¡ÉÒ¹Ò¹ 2 à´×͹áÅéÇÍÒ¡ÒÃäÁè´Õ¢Öé
¹
ÂѧÁÕ
¼Å¡ÒõÃǨàÊÁËÐà»ç¹ºÇ¡
ËÃ×ÍàÊÁËÐà»ÅÕ蹨ҡź
à»ç¹ºÇ¡

¶×ÍÇèÒ¡ÒÃÃÑ¡ÉÒÅéÁàËÅÇ
ËҡʧÊÑÂÇèÒ¡ÒÃÃÑ¡ÉÒ
ÅéÁàËÅǨҡ¡Òô×éÍÂÒ
ãËéà¾ÒÐàª×éÍÊÔè§Ê觵ÃǨÍÕ¡¤ÃÑé
§
ÃÇÁ¶Ö§¡Ò×´Êͺ¤ÇÒÁäǵèÍÂÒ
á¹Ð¹ÓãËéà¾ÔèÁÂÒÍÕ
¡
ÍÂèÒ§¹éÍ 2 ª¹Ô
´
ÃÐËÇèÒ§ÃͼÅà¾ÒÐàª×éÍáÅФÇÒÁäÇ
µèÍÂÒ
à¾×èÍÅ´âÍ¡ÒÊ¡ÒôÓà¹Ô¹µèͧ͢¡Òô×éÍÂÒ
ÍÂèÒ§
äáç
´Õ¤ÇûÃÖ¡ÉÒ¼ÙéàªÕèÂǪҍ੾ÒЗҧ´éÇÂ
ÃÐÂÐàÇÅÒ
6 à´×͹
6-9 à´×͹
6 à´×͹
6 à´×͹
9-12 à´×͹
6 à´×͹
6 à´×͹
6 à´×͹
â´Â»¡µÔäÁè¨Óà»ç¹µéͧµÃǨ¡Ò×ӧҹ¢Í§µÑ
º
áÅÐ䵗ءÃÒÂ
¶éÒäÁèÁÕ¤ÇÒÁ¼Ô´»¡µÔµÑé§áµè¡è͹¡ÒÃÃÑ¡ÉÒ
ÃÒ—ÕèÁÕ¤ÇÒÁ¼Ô´»¡µÔ¢Í§µÑºËÃ×Íäµ
ËÃ×ÍÁÕÍÒ¡Ò×Õè
ºè§ºÍ¡¤ÇÒÁ¼Ô´»¡µÔ¤ÇõÃǨµÔ´µÒÁ¡Ò×ӧҹÍÂèÒ§
µèÍà¹×èͧ
ÃÇÁ¶Ö§µÃǨÇÑ´ÃдѺÊÒµÒáÅСÒÃÁͧàËç
¹
ÊÕã¹ÃÒ—Õèä´éÃѺÂÒÍÕá—ÁºÙ—ÍÅ
ÁÒ¡¡ÇèÒ 10-15
ÁÔÅÅÔ¡ÃÑÁµè͹éÓ˹ѡµÑÇ1 ¡ÔâÅ¡ÃÑÁµèÍÇÑ
¹
ËÃ×ÍÃѺ»ÃЗҹ
ÂÒÁÒ¹Ò¹¡ÇèÒ 2 à´×͹
¡ÒÃãªéÂÒª¹Ô´àÁç´ÃÇÁ42
à¹×èͧ¨Ò¡¡ÒÃÃÑ¡ÉÒÇѳâäµéͧãªéÂÒËÅÒª¹Ô
´
ÃèÇÁ¡Ñ
¹
ÃÇÁ—Ñ駻ÃѺ¢¹Ò´ÂÒµÒÁ¹éÓ˹ѡµÑǢͧ¼Ùé»èÇÂ
—ÓãËéµéͧÃѺ»ÃЗҹÂÒ¶Ö§ 9-12 àÁç´µèÍÇÑ
¹
ã¹ÃÐÂÐ
2 à´×͹áá
áÅÐ 3-9 àÁç´µèÍÇÑ
¹

ã¹ÃÐÂÐ 4-6 à´×͹
¶Ñ´ÁÒ
¨Ö§ÁÕ¡ÒùÓÂÒª¹Ô´àÁç´ÃÇÁÁÒãªéà¾×èÍãËé¨Ó¹Ç¹
àÁç´ÂÒÅ´àËÅ×Íà¾Õ§ 3-5 àÁç´µèÍÇÑ
¹
«Ö觧èÒµèÍ¡ÒÃÃÑ
º
»ÃЗҹÂÒ
»éͧ¡Ñ¹¡ÒÃÃѺ»ÃЗҹÂÒäÁè¤Ãº
—Ñ駹ÕéÂÑ
§
§èÒµèÍ¡Òäӹdz¢¹Ò´ÂÒáÅСÒÃÊÑè§ÂҢͧᾗÂ
ì
ÃÒ§ҹ¨Ò¡»ÃÐà—ÈÎèͧ¡§
ã¹»Õ¾.È. 2532 ¾ºÇè
Ò
à¾Õ§
ÃéÍÂÅÐ 1 ¢Í§¼Ùé»èÇ—ÕèÃѺ»ÃЗҹÂÒª¹Ô´àÁç´ÃÇÁ—Ñé
§

¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
ËÁ´ 312 ÃÒ—ÕèáÊ´§¤ÇÒÁàËç¹à¡ÕèÂǡѺ¤ÇÒÁÅÓºÒ¡ã¹
¡ÒÃÃѺ»ÃЗҹÂÒ
à»ÃÕºà—Õº¡ÑºÃéÍÂÅÐ 5 ¢Í§¼Ùé»èÇÂ
308 ÃÒÂ
—ÕèÃѺ»ÃЗҹÂÒª¹Ô´á¡àÁç
´
Êèǹ¼Å¢éÒ§à¤Õ§
¨Ò¡ÂÒ
¾ºÇèÒà—èҡѹ—Ñé§Êͧ¡ÅØè
Á
Êèǹ»ÃÐà—ȺÃÒ«Ô
Å
áÅÐáÍ¿ÃÔ¡Òãµé¡ç¾º»ÑËÒ¡Òô×éÍÂÒŴŧ (ÃéÍÂÅÐ
5.4 ŴŧàËÅ×ÍÃéÍÂÅÐ 0.9 áÅÐÃéÍÂÅÐ 4 ŴŧàËÅ×
Í
ÃéÍÂÅÐ 1.1 µÒÁÅӴѺ) ËÅѧ¨Ò¡ãªéÂÒª¹Ô´àÁç´ÃÇÁã¹
»Õ¾.È. 2537-2540
»Ñ¨¨ØºÑ¹»ÃÐà—ÈÊËÃÑ°ÍàÁÃÔ¡Ò
ÁÕ¡ÒÃãªéÂÒäÃ
¿ÒàÁ— (rifamate) «Öè§à»ç¹Êèǹ¼ÊÁ¢Í§ÂÒäÍâ«ä¹
ÍÐÊÔ´ 150 ÁÔÅÅÔ¡ÃÑ
Á
áÅÐäÃá¿Á¾Ô«Ô¹ 300 ÁÔÅÅÔ¡ÃÑ
Á
ÍÕ¡ª¹Ô´Ë¹Ö觤×
Í
äÿÒàµÍÃì (rifater) «Ö觼ÊÁÂÒäÍâ«
ä¹ÍÐÊÔ´ 50 ÁÔÅÅÔ¡ÃÑ
Á
ÂÒäÃá¿Á¾Ô«Ô¹ 120 ÁÔÅÅÔ¡ÃÑ
Á
áÅÐÂÒä¾ÃÒ«Ô¹ÒäÁ´ì 300 ÁÔÅÅÔ¡ÃÑ
Á
ºÒ§»ÃÐà—ÈÍÒ¨
ÁÕ¡ÒüÊÁÂÒËÅÑ¡—Ñé§ 4 ª¹Ô
´
ã¹àÁç´à´ÕÂÇ
ÂÒª¹Ô´àÁç
´
ÃÇÁàËÁÒÐÊÓËÃѺÊÙµÃÇѹÅФÃÑé
§
ºÒ§áËè§ÍÒ¨ÁÕ¡ÒÃãªé
ÂÒäÿÒàÁ—¤Ùè¡ÑºÂÒäÍâ«ä¹ÍÐÊÔ´ÊÑ»´ÒËìÅÐ 2 ¤ÃÑé
§
ÍÂèÒ§
äáç
´ÕáÁéäÁèÁÕËÅÑ¡°Ò¹Â×¹Âѹá¹èªÑ´ÇèÒÂÒª¹Ô´àÁç´ÃÇÁ
ÁÕ»ÃÐÊԗ¸ÔÀÒ¾à˹×Í¡ÇèÒÂÒª¹Ô´á¡
áµè¼ÙéàªÕèÂǪҍ
ËÅÒ—èÒ¹á¹Ð¹ÓãËéãªéÂÒª¹Ô´àÁç´ÃÇÁ
ã¹ÃÒ—ÕèäÁè
ÊÒÁÒöÃѺ»ÃЗҹÂÒª¹Ô´á¡àÁ紗ءÇѹẺÇÔ

¸Õ
DOTs ä´é
´Ñ§¹Ñé
¹
ͧ¤ì¡ÒÃ͹ÒÁÑÂâÅ¡ (WHO) áÅÐ
International Union Against Tuberculosis and
Lung Disease (IUATLD) ŧ¤ÇÒÁàËç¹ÇèÒ¡ÒÃãªéÂÒ
ª¹Ô´àÁç´ÃÇÁÁÕ¢éÍ´Õ¤×
Í
ºÃÔËÒÃÂÒ§èÒÂ
Å´¤ÇÒÁ¼Ô´¾ÅÒ´
¨Ò¡¡ÒÃÃѺ»ÃЗҹÂÒ
—ÓãËéÅ´âÍ¡ÒÊà¡Ô´¡Òô×éÍÂÒä´é
ã¹Í¹Ò¤µ
¨Ö§ÁÕÊÙµÃÂÒª¹Ô´àÁç´ÃÇÁµÒÁµÒÃÒ§—Õè 7 à»ç
¹
µé
¹
¶Ö§¡ÃйÑ鹡çµÒÁáÁéÇèÒãªéÂÒª¹Ô´àÁç´ÃÇÁáÅé
Ç
áµè
ͧ¤ì¡ÒÃ͹ÒÁÑÂâÅ¡Âѧá¹Ð¹ÓãËéãªéÇÔ¸Õ DOTs ¤Çº¤Ùèä»
´éÇÂ
µÒÃÒ§—Õè 7. áÊ´§ÊÙµÃÂÒª¹Ô´àÁç´ÃÇÁª¹Ô´µèÒ§æ—Õèä´éÃѺ¡ÒÃá¹Ð¹Ó¨Ò¡ WHO
R : rifampicin, H : isoniazid, Z : pyrazinamide, E : ethambutol
ª¹Ô´ÂÒÃÇÁ
¢¹Ò´ÂÒ
Rifampicin + isoniazid +
pyrazinamide + ethambutol
R 150 mg + H 75 mg + Z 400 mg + E 275 mg
Rifampicin + isoniazid + pyrazinamide R 150 mg + H 75 mg + Z 400 mg
R 60 mg + H 30 mg + Z 150 mg (paediatric)
R 60 mg + H 30 mg (paediatric)
Isoniazid + ethambutol H 150 mg + E 400 mg
Thioacetazone + isoniazid T 50 mg + H 100 mg
T 150 mg + H 300 mg

»Õ—Õè 19 ©ºÑº—Õè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
¢éͤÇÃÃÐÇѧ¢Í§¡ÒÃãªéÂÒª¹Ô´àÁç´ÃÇÁ¤×
Í
äÁè
ä´éÃдѺ—Õèãªéä´é (bioavailability) ¢Í§ÂÒäÃá¿Á¾Ô
«Ô
¹
â´ÂÍÒ¨à¡Ô´¨Ò¡¡ÒüÅÔµÂҗÕèäÁèä´éÁҵðҹ
ËÃ×
Í
¡Òôٴ«ÖÁÂÒäÁè´Õã¹¼Ùé»èÇ—ÕèÁÕâä—Ò§ÍÒÂØáÃÃÁÃèÇÁ
àªè
¹
âäàÍ´Ê
ì—ÓãËé¡ÒÃãªéÂÒäÁèä´éÁҵðҹ
¡èÍãËéà¡Ô´¡ÒÃ
ÃÑ¡ÉÒÅéÁàËÅÇáÅд×éÍÂÒµÒÁÁÒ
¡Òô×éÍÂÒ
»ÑËÒàª×éÍÇѳâä´×éÍÂÒÁÒ¡¡ÇèÒ˹Ö觪¹Ô´¹Ñé
¹
ÂÒ¡
µèÍ¡ÒÃÃÑ¡ÉÒ
¨Ò¡¡ÒÃÊÓÃǨ¢Í§ Dye áÅФ³Ð46 ã¹¼Ùé
»èÇÂÇѳâäÃÒÂãËÁèÃÇÁ 136 »ÃÐà—È
ÁÕ¡Òô×éÍÂÒËÅÒÂ
¢¹Ò¹
¶Ö§ÃéÍÂÅÐ 3.2 ¡ÒÃà¡Ô´¡ÒþѲ¹Ò¢Í§àª×éÍà»ç
¹
ÊÒ¾ѹ¸ìؗÕè´×éÍÂÒ
â´Â¡Ò×Õèàª×éÍÇѳâä¾Ñ²¹ÒÊÒ¾ѹ¸
ìØ
´×é͵èÍÂÒà¾Õ§˹Ö觪¹Ô
´
äÁè—ÓãËéà¡Ô´¡Òô×éÍÂҗÕèÊÓ¤Ñ

—Ò§¤ÅÔ¹Ô
¤
àª×éÍÇѳâäÁÑ¡´×é͵èÍÂÒäÍâ«ä¹ÍÐÊÔ
´
(isoniazid) ÁÒ¡—ÕèÊØ
´
¡èÍãËéà¡Ô´¡Òô×é͵èÍÂÒäÃá¿Á¾Ô
«Ô¹ (rifampicin) µÒÁÁÒ
àÁ×èÍàª×éÍ´×é͵èÍÂÒËÅÒª¹Ô
´
ÁÒ¡¢Öé
¹
¨Ö§—ÓãËé¡ÒÃÃÑ¡ÉÒäÁèä´é¼Åà—èҗÕè¤ÇÃ
ÍÂèÒ§äÃ
¡ç
´ÕÊèǹãˍèÁÑ¡à¡Ô´¡Òô×éÍÂÒÀÒÂËÅÑ
§
àªè

¹
ÁÕàª×éÍ»ÃÔÁÒ³
ÁÒ¡ã¹â¾Ã§¢Í§»Í´
¡ÒÃÃѺ»ÃЗҹÂÒäÁèÊÁèÓàÊÁÍ
äÁè
¶Ù¡µéͧµÒÁÊÙµÃËÃ×Í¢¹Ò´ÂÒ
¹Í¡¨Ò¡¹Õé¤ÇÃʧÊÑ
Â
ã¹
¡Ã³Õ—ÕèÁÕ»ÃÐÇѵÔà¤ÂÃÑ¡ÉÒÇѳâäÁÒ¡è͹
ÊÑÁ¼ÑÊã¡ÅéªÔ
´
¼Ùé»èÇÂÃÒÂÍ×蹗ÕèÁÕËÅÑ¡°Ò¹ÇèÒ´×éÍÂÒ
ËÃ×ÍÍÂÙèã¹¾×鹗Õè—Õè
ÁÕ
ÍغѵԡÒóì¡Òô×éÍÂÒÊÙ
§
«Ö觗ÓãËé¡ÒÃÃÑ¡ÉÒÅéÁàËÅÇ
¨Ö
§
ÁÕ¡ÒÃá¹Ð¹ÓÇÔ¸Õ¡ÒôÙáżÙé»èÇÂÇѳâä´×éÍÂÒ (µÒÃÒ§—Õè 7)
áÅСÒùÓÂÒª¹Ô´µèÒ§æÁÒãªé¹Í¡à˹×ͨҡÊÙµÃÂÒËÅÑ
¡
(µÒÃÒ§—Õè 8) ÍÂèÒ§äáç
´ÕÂÒàËÅèÒ¹ÕéÁռŢéÒ§à¤Õ§ÁÒ¡¡Çè
Ò
ÃÒ¤Òᾧ¡Çè
Ò
ÃÇÁ—Ñ駻ÃÐÊԗ¸ÔÀÒ¾´éÍ¡ÇèÒÊÙµÃÂÒËÅÑ
¡
¡ÒÃãªéÂÒËÃ×ÍàÅ×Í¡ÊÙµÃÂÒ¤ÇÃä´éÃѺ¤Óá¹Ð¹Ó¨Ò¡¼ÙéàªÕèÂÇ
ªÒà©¾ÒÐ
ÃÇÁ¶Ö§¡ÒÃÃѺ»ÃЗҹÂÒâ´ÂÁÕ¼ÙéÊѧࡵ¡Òó
ì
àÃÕ¡ÇÔ¸Õ directly observed therapys (DOTs)
ÃÒ§ҹ¨Ò¡ Weis ¾ºÇèÒÍѵÃÒ¡Òô×éÍÂÒáÅСÒáÅÑ
º
à»ç¹«éÓŴŧ㹡ÅØèÁ—ÕèãªéÇÔ¸Õ DOTs
ÀÒ¾áÊ´§¤ÇÒÁªØ¡¢Í§¡Òô×éÍÂÒÃÑ¡ÉÒÇѳâä㹼Ùé»èÇÂÃÒÂãËÁè
»Õ¾.È. 2537-2543 ÃÒ§ҹ¨Ò¡ WHO48

¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
µÒÃÒ§—Õè 7. ¤Óá¹Ð¹Ó㹡ÒôÙáżÙé»èÇÂÇѳâä´×éÍÂÒ
DOTs : directly observed therapy
-äÁèà¾ÔèÁÂÒà¾Õ§µÑÇà´ÕÂÇ㹡ÒÃÃÑ¡ÉÒÇѳâä´×éÍÂÒ
-àÁ×èÍàÃÔèÁ¡ÒÃÃÑ¡ÉÒãËÁè¤ÇùÓÂҗÕèäÁèà¤ÂãªéÍÂèÒ§¹éÍ 3 ª¹Ô
´
Áҗ´Êͺ¤ÇÒÁäǢͧàª×é
Í
â´Â 1 ª¹Ô
´
¤ÇÃà»ç¹ª¹Ô´©Õ
´
-ÍÒ¨ãªéÂÒä´é¶Ö§ 4-6 ª¹Ô´ã¹ÃÒ—Õè´×éÍÂÒËÅÒ¢¹Ò¹
-¤ÇÃãªéÇÔ¸Õ DOT ã¹¼Ùé»èÇ—ءÃÒÂ
-äÁè¤ÇÃÃѺ»ÃЗҹÂÒẺàÇé¹ÇÑ
¹
¤ÇÃãªéÊÙµÃÂÒẺÃѺ»ÃЗҹ—Ø¡ÇÑ
¹
¡àÇ鹪¹Ô´©Õ
´
-äÁè¤ÇÃãªéÂҗÕè¼Å¡Ò×´Êͺ—Ò§Ëéͧ»‾ԺѵԡÒÃÃÒ§ҹÇèÒ´×éÍÂÒ
-¡Òô×éÍÂÒäÃá¿Á»Ô¹ÁÑ¡´×éÍÂÒäÿҺٵԹáÅÐäÿÒà¾ç¹µÔ¹´éÇÂ
-äÁ辺¡Òô×éÍ¢éÒÁ¡Ñ¹ÃÐËÇèÒ§ÂÒÊàµÃçºâµäÁ«Ô¹áÅÐÂÒ©Õ´Í×è¹æ
-äÁè¹ÔÂÁãªéÂÒ©Õ´ 2 ª¹Ô´¾ÃéÍÁ¡Ñ
¹
à¹×èͧ¨Ò¡ÂѧäÁèä´éÃѺ¡ÒÃÂ×¹Âѹ»ÃÐÊԗ¸ÔÀÒ¾áÅмŢéÒ§à¤Õ§
-ËÒ¡¾º¡Òô×éÍÂÒÊàµÃçºâµäÁ«Ô¹ª¹Ô´à´ÕÂÇ
ãËéÃÐÇѧàª×é
Í
M. bovis ÁÒ¡¡Çè
Ò
M. tuberculosis
µÒÃÒ§—Õè 8 ÊÙµÃÂÒÃÑ¡ÉÒÇѳâä»Í´´×éÍÂÒ

»Õ—Õè 19 ©ºÑº—Õè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
àÍ¡ÊÒÃÍéÒ§ÍÔ
§
1.
Harrison's Principles of Internal Medicine
16th Edition. Tuberculosis chap 150, pp
2.
World Health Organization Fact sheet no
104, revised March 2004. Geneva
(Switzerland)7 World Health Organization;
2004.
3.
Gardner CA, Acharya T, Pablos-Mendez
A. The global alliance for tuberculosis
drug development accomplishments and
future directions. Clin Chest Med. 2005
26:341-7.
4.
ÊÁÒ¤Á»ÃÒºÇѳâäáË觻ÃÐà—Èä—Âã¹¾ÃкÃÁÃÒ
ªÙ»¶ÑÁÀì, ¡ÃÁ¤Çº¤ØÁâäµÔ´µè
Í
¡ÃЗÃǧ
ÊÒ¸ÒóÊØ
¢
ÊÁÒ¤ÁÍØÃàǪªìáË觻ÃÐà—Èä—Â.
á¹Ç—Ò§¡ÒÃÇÔ¹Ô¨©ÑÂáÅÐÃÑ¡ÉÒÇѳâä㹻ÃÐà—Èä—
Â
¾ÔÁ¾ì¤ÃÑ駗Õè 2 (©ºÑº»ÃѺ»Ãا)
5.
ÈÙ¹Âì¢éÍÁÙÅâäµÔ´àª×éÍáÅоÒËйÓâä
6.
Jawahar, Current trends in chemotherapy
of tuberculosis. Indian J Med Res, Oct
2004,pp398-417.
7.
Rich A, Follis RH. 1938. The inhibitory
effect of sulfanilamide on the development
of experimental tuberculosis of the guinea
pig. Bull. Johns Hopkins Hosp.62:77-84.
8.
Waksman SA. Suppressive effect of
streptomycin on the growth of tubercle
bacilli in laboratory animals. Am J Public
Health 1944;34:358.
9.
Benator D, Bhattacharya M, Bozeman L,
Burman W, Cantazaro A, Chaisson R,
et al. Tuberculosis Trials Consortium.
Rifapentine and isoniazid once a week
versus rifampicin and isoniazid twice a
week for treatment of drug-susceptible
pulmonary tuberculosis in HIV-negative
patients: a randomised clinical trial. Lancet.
2002;360:528-34.

10.
Lehmann J. 1946. p-aminosalicylic acid
in the treatment of tuberculosis. Lancet
1:15-16.
11.
TEMPEL CW, HUGHES FJ Jr, MARDIS
RE, TOWBIN MN, DYE WE. Combined
intermittent regimens employing
streptomycin and para-aminosalicylic acid
in the treatment of pulmonary tuberculosis;
a comparison with daily and intermittent
dosage schedules. Am Rev Tuberc.
1951;63:295-311.
12.
Mitchison DA. Role of individual drugs
in the chemotherapy of tuberculosis. Int
J Tuberc Lung Dis. 2000;4:796-806.
13.
East African/British Medical Research
Councils Study. Results at 5 years of a
controlled comparison of a 6-month and
a standard 18-month regimen of
chemotherapy for pulmonary tuberculosis.
Am Rev Respir Dis 1977;116:3-8.
14.
East African/ British Medical Research
Councils. Controlled clinical trial of shortcourse (6-month) regimens of chemotherapy
for treatment of pulmonary
tuberculosis. Lancet 1972;1:1079-85.
15.
American Thoracic Society, Centers for
Disease Control and Prevention, and
Infectious Diseases Society of America.
Treatment of tuberculosis. MMWR
Recomm Rep 2003;52:1-77.

¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
16.
American Thoracic Society, CDC and
Prevention, and Infectious Diseases Society
of America. Update recommendation for
treatment of tuberculosis. Am family phy.
Nov 2003.
17.
Sahbazian B, Weis SE. Treatment of active
tuberculosis: challenges and prospects. Clin
Chest Med. 2005;26:273-82.
18.
American Thoracic Society, Centers for
Disease Control and Prevention. Treatment
of tuberculosis and tuberculosis infection
in adults and children. Am J Respir Crit
Care Med 1994;149:1359-74.
19.
Up to date version 13.2.
20.
Somoskovi et al. Review The molecular
basis of resistance to isoniazid, rifampin,
and pyrazinamide in Mycobacterium
tuberculosis Respiratory Research 2001
Vol 2 No 3.
21.
Black M, Mitchell JR, Zimmerman HJ,
Ishak KG, Epler GR. Isoniazid-associated
hepatitis in 114 patients. Gastroenterology.
1975;69:289-302.
22.
Garibaldi RA, Drusin RE, Ferebee SH,
Gregg MB. Isoniazid-associated
hepatitis. Report of an outbreak. Am
Rev Respir Dis. 1972;106:357-65.
23.
American Thoracic Society. Report on
the Ad Hoc Committee on isoniazid and
liver disease. Centers for Disease Control,
Department of Health, Education and
Welfare. March 17-18, 1971. Isoniazid and
liver disease. Am Rev Respir Dis 1971;
104:454.
24.
Steele MA, Burk RF, DesPrez RM. Toxic
hepatitis with isoniazid and rifampin. A
meta-analysis. Chest. 1991;99:465-71.
25.
Nolan CM, Goldberg SV, Buskin SE.
Hepatotoxicity associated with isoniazid
preventive therapy: a 7-year survey
from a public health tuberculosis clinic.
JAMA. 1999;281:1014-8.
26.
Grosset J, Leventis S. Adverse affects of
rifampin. Rev Infect Dis 1983;5:S440-50.

27.
Shoen CM, DeStefano MS, Cynamon MH.
2000. Durable cure for tuberculosis: rifalazil
in combination with isoniazid in a murine
model of Mycobacterium tuberculosis
infection. Clin. Infect. Dis. 30(Suppl.
3):S288-90.
28.
Yee, Valiquette, Pelletier, et al.: Side
Effects of TB Therapy. Am J Respir Crit
Care Med Vol 167. pp 1472-1477, 2003.
29.
Pilheu JA, Maglio F, Cetrangolo R, Pleus
AD. Concentrations of ethambutol in the
cerebrospinal fluid after oral administration.
Tubercle. 1971;52:117-22.
30.
Leibold JE. The ocular toxicity of
ethambutol and its relation to dose.
Ann N Y Acad Sci. 1966;135:904-9.
31.
Murray FJ. A pilot study of cycloserine
toxicity: a United States Public Health
Service cooperative clinical investigation.
Am Rev Respir Dis 1956;74:196-209.
32.
Joint Committee on the Study of
Streptomycin. The effects of streptomycin
on tuberculosis in man. JAMA 1947;135:
634-41.

»Õ—Õè 19 ©ºÑº—Õè 4 µØÅÒ¤Á -¸Ñ¹ÇÒ¤Á
2549
33.
Black RE, Lau WK, Weinstein RJ, Young
LS, Hewitt WL. Ototoxicity of amikacin.
Antimicrob Agents Chemother. 1976;9:95661.
34.
Rossouw JE, Saunders SJ. Hepatic
complications of antituberculous therapy.
Q J Med 1975;XLIV:1-16.
35.
Nuermberger EL, Yoshimatsu T, Tyagi
S, O Brien RJ, Vernon AN, Chaisson RE,
Bishai WR, Grosset JH. Moxifloxacincontaining
regimen greatly reduces time
to culture conversion in murine
tuberculosis. Am J Respir Crit Care Med.
2004;169:421-6.
36.
David HL. Probability distribution of
drug-resistant mutants in unselected
populations of Mycobacterium
tuberculosis. Appl Microbiol.
1970;20:810-4.
37.
Centers for Disease Control and Prevention.
Prevention and treatment of tuberculosis
among patients infected with human
immunodeficiency virus: principles of
therapy and revised recommendations.
MMWRMorb Mortal Wkly Rep 1998;47
:1-51.
38.
Horsburgh CR Jr, Feldman S, Ridzon R;
Infectious Diseases Society of America.
Practice guidelines for the treatment of
tuberculosis. Clin Infect Dis. 2000;31:6339.
39.
Essential components of a tuberculosis
control program: recommendations of the
Advisory Council for the Elimination of
Tuberculosis. MMWR Morb Mortal Wkly
Rep 1995;44:1-16.
40.
Treatment of tuberculosis: Guidelines of
national programs. 3rd ed. Geneva: WHO;
2003.
41.
Mitchison DA, Nunn AJ. Influence of
initial drug resistance on the response to
short-course chemotherapy of pulmonary
tuberculosis. Am Rev Respir Dis.
1986;133:423-30.
42.
Bjorn Blomberg, Sergio Spinaci,Bernard
Fourie,Richard Laing. The rationale for
recommending fixed-dose combination

tablets for treatment of tuberculosis.
Bulletin of the World Health Organization,
2001,79:61-8.
43.
Hong Kong Chest Service/British Medical
Research Council. Acceptability,
compliance, and adverse reactions when
isoniazid, rifampin, and pyrazinamide are
given as a combined formulation or
separately during three-times-weekly
antituberculosis chemotherapy. American
Review of Respiratory Disease, 1989,140:
1618-22.
44.
Pablos-Mendez Aet al. Global surveillance
for antituberculosis drug resistance, 19941997.
World Health Organization
International Union against Tuberculosis
and Lung Disease Working Group on
Anti-Tuberculosis Drug Resistance
Surveillance. N Engl J Med, 1998;338:
1641-9.

¡ÒÃãªéÂÒÃÑ¡ÉÒÇѳâä
¨ØÌÒÍÒÂØÃÈÒʵÃ
ì
45.
The use of essential drugs: ninth report of
the WHO Expert Committee (including
the revised Model List of Essential Drugs).
Geneva, World Health Organization, 2000
(WHO Technical Report Series, No. 895)
46.
Dye C, Espinal MA, Watt CJ, Mbiaga
C, Williams BG. Worldwide incidence of
multidrug-resistant tuberculosis. J Infect
Dis 2002;185:1197-202.
47.
Weis SE, Slocum PC, Blais FX, et al.
The effect of directly observed therapy
on the rates of drug resistance and relapse
in tuberculosis N Engl J Med 1994;330:117984.
48.
Iruka N Okeke,et al. Antimicrobial
resistance in developing countries. Part I:
recent trends and current status. Lancet
Infect Dis 2005;5:481-93.

Sponsor Documents

Or use your account on DocShare.tips

Hide

Forgot your password?

Or register your new account on DocShare.tips

Hide

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close